Mass Spectrometry-Based High Throughput Approach for Identification of Molecular Modification of Oxidative Process in Respiratory Diseases by Song, Wei
Cleveland State University
EngagedScholarship@CSU
ETD Archive
2008
Mass Spectrometry-Based High Throughput
Approach for Identification of Molecular
Modification of Oxidative Process in Respiratory
Diseases
Wei Song
Cleveland State University
Follow this and additional works at: https://engagedscholarship.csuohio.edu/etdarchive
Part of the Chemistry Commons
How does access to this work benefit you? Let us know!
This Dissertation is brought to you for free and open access by EngagedScholarship@CSU. It has been accepted for inclusion in ETD Archive by an
authorized administrator of EngagedScholarship@CSU. For more information, please contact library.es@csuohio.edu.
Recommended Citation
Song, Wei, "Mass Spectrometry-Based High Throughput Approach for Identification of Molecular Modification of Oxidative Process
in Respiratory Diseases" (2008). ETD Archive. 277.
https://engagedscholarship.csuohio.edu/etdarchive/277
 MASS SPECTROMETRY-BASED HIGH THROUGHPUT 
APPROACH FOR IDENTIFICATION OF MOLECULAR 
MODIFICATION OF OXIDATIVE PROCESS IN RESPIRATORY 
DISEASES 
 
WEI SONG 
Bachelor of Science in Medicinal Chemistry 
Beijing Medical University 
June 1996 
 
 
submitted in partial fulfillment of requirements for the degree 
DOCTOR OF PHILOSOPHY IN CLINICAL-BIOANALYTICAL CHEMISTRY 
at the 
CLEVELAND STATE UNIVERSITY 
November 2007 
This Dissertation has been approved 
For the Department of CHEMISTRY 
And the College of Graduates Studies by 
 
       
Dissertation Committee Co-Chairman, Dr. Stanley L. Hazen 
Department of Cell Biology, Lerner Research Institute, Cleveland Clinic 
 
       
Dissertation Committee Co-Chairman, Dr. Lily M. Ng 
Department of Chemistry, Cleveland State University 
 
       
Dissertation Committee Member, Dr. Serpil Erzurum 
Department of Pathobiology, Lerner Research Institute, Cleveland Clinic 
 
       
Dissertation Committee Member, Dr. Baochuan Guo 
Department of Chemistry, Cleveland State University 
 
       
Dissertation Committee Member, Dr. Michael T. Kinter 
Department of Cell Biology, Lerner Research Institute, Cleveland Clinic 
 DEDICATION AND ACKNOWLEDGEMENTS 
 
I want to thank the Cleveland State University and Lerner Research Institute of 
Cleveland Clinic Foundation joined program for providing me this golden opportunity to 
perform my research at Dr. Hazen’s Lab.  I deeply and gratefully thank my dissertation 
advisor Dr. Hazen and academic advisor Dr. Ng for their exceptional mentorship, 
constant support, unlimited encouragement and patience.  The training they gave me will 
be an important part of my future scientific achievements.  For everything you have done 
for me, Dr. Hazen and Dr. Ng, I thank you! 
I gratefully acknowledge Dr. Erzurum, Dr. Guo and Dr. Kinter for being on my 
committee member, and for their support, motivation and valuable input.  Their 
understanding and support play an important role in my research.   
I extend my sincere appreciation to Dr. Brennan for her training and assistance in 
animal study.  I want to thank Dr. Citardi for his help in clinical study.  I also want to 
thank Dr. Levison and Dr. Zhang for technical support in Mass Spectrometry.  Special 
thanks are given to Xiaoming Fu and David Schmitt for their assistance.  I like to 
acknowledge all my co-workers and friends in Dr. Hazen’s lab for their unlimited support.   
I like to thank my husband, Yu for his support, encouragement and unwavering 
love.  Finally, and most importantly, I like to thank my parents for their love, guidance 
and support.   
 
MASS SPECTROMETRY-BASED HIGHTHROUGHPUT APPROACH FOR 
IDENTIFICATION OF MOLECULAR MODIFICATION OF OXIDATIVE 
PROCESS IN RESPIRATORY DISEASES 
WEI SONG 
ABSTRACT 
 
Eosinophil peroxidase (EPO) and myeloperoxidase (MPO) have been implicated 
in generating reactive species and promoting oxidative modifications in numerous 
diseases.  The detection and identification of potential pathways has been proven 
extremely challenge due to evanescence nature of these reactive species.  An alternative 
approach to study the involvement of oxidative modification is to detect and quantify the 
stable molecular fingerprints, like oxidized tyrosine species, in biological matrices.   
Previously reported analytical methods for quantifying oxidized amino acids have 
typically been limited by: low sensitivity, specificity and the failure of detection potential 
oxidation products generated during sample handling. Using GC/MS in combination with 
stable isotope dilution, a sensitive and self-quality control assay was developed.  Using 
this isotope-dilution GC/MS and multiple allergen challenge models, we demonstrate that 
EPO is the major pathway for generating protein-bound 3-bromotyrosine in vivo.   
However, the need for chemical derivatization of samples increases the possibility 
that artifactual generation of oxidation products which may interfere with the detection of 
native levels.  Requirement of unique derivatization reagent for each oxidized tyrosine 
results sample analysis both cumbersome and time/labor intensive.  Therefore, we 
develop a liquid chromatography with on-line electrospray ionization tandem mass 
 iv
spectrometry (LC-ESI/MS/MS) assay that simultaneously detects and quantifies multiple 
structurally informative protein oxidation products along with their precursor amino acids.  
Use of four HPLC systems in multiplex array with column switching permits on-line 
analyses of only relevant portions of chromatographic profiles and up to four-fold 
increased throughput efficiency of mass detector usage.  
Using this high-throughput multiplexed array-based LC-MS/MS method, we 
found significant correlations among individual oxidized tyrosine in sera from healthy 
volunteers.  These correlations provide chemical evidence that activated leukocytes 
utilize various physiological available substrates to participate multiple oxidative 
modifications in vivo.  In rhinosinusitis study, significantly elevated protein-bound 
oxidized tyrosine species were detected in healthy nasal tissue compared to that at the 
peripheral level.  In addition, rhinosinusitis patients had more severe oxidative 
modification in their nasal tissue.  The evidence supports elevated bromination and 
tyrosylation may contribute to the pathogenesis of rhinosinusitis. 
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CHAPTER I  
PEROXIDASE AND PEROXIDASE CATALYZED OXIDATIVE 
DAMAGES 
 
 
Peroxidases are heme-containing enzymes that catalyze the reduction of hydrogen 
peroxide (H2O2) and facilitate the generation of various reactive species as part of the 
innate host defense system 1-3.  The mammalian peroxidase super-family includes 
eosinophil peroxidase (EPO), lactoperoxidase (LPO), myeloperoxidase (MPO), 
prostaglandin H1/2 synthases (PGHS-1, PGHS-2) and thyroid peroxidase (TPO) 4.  The 
major function of EPO and MPO is involved in protecting the host from infectious 
diseases 5, 6.  Evidences indicate that EPO and MPO may also play a vital role in 
facilitating oxidative modifications by generating reactive oxygen species in numerous 
diseases such as asthma, rhinosinuositis, atherosclerosis and multiple sclerosis 7-9.   
In this chapter, a brief review includes following topics: (1) Eosinophil peroxidase 
(EPO) and myeloperoxidase (MPO); (2) Catalytic site of EPO and MPO; (3) Peroxidase 
catalyzed oxidationand inflammatory diseases.     
 1
1.1 Eosinophil Peroxidase (EPO) and Myeloperoxidase (MPO) 
Eosinophil peroxidase (EPO) and Myeloperoxidase (MPO) share a high degree 
homology at genomic sequence level and in physiological function.  Genetic studies 
reveal that human EPO and human MPO are encoded by adjacent genes located on 
human chromosome 17 4, 10.  DNA sequence studies reveal that EPO and MPO gene both 
contain 12 exons and 11 introns.  Further, human EPO and human MPO have an overall 
72.4% homology at nucleotide level and 69.8% homology at amino acids level 11.  
Elevated eosinophils, neutrophils and increased EPO, MPO contents are associated with 
numerous disorder including allergic respiratory diseases, cardiovascular diseases and 
neurodegenerative disorders 12, 13.  Upon stimulation, eosinophils and neutrophils are 
recruited to the inflammation sites and release their specific granule proteins, including 
peroxidases 14, 15.  Peroxidases utilize H2O2 and various substrates to generate cytotoxic 
oxidants to fight invading pathogens 16, 17.   
Genetic Properties of MPO and EPO 
Genomic studies of MPO and EPO were started in the middle 1980s.  Morishita et 
al. used a synthetic 41-base oligonucleotide, which was decoded from amino acid 
sequence of human myeloperoxidase, as a probe to isolate MPO cDNA clones from 
human promyelocytic leukemia HL-60 cell.  They identified a 2.6-kilobase nucleotide 
that contained genetic information for a polypeptide which had 745 amino acids.  The 
calculated molecular weight was estimated of 83 kDa.  Human MPO heavy chain was 
located on the C terminus of this particular polypeptide. 18.  Yamada et al. isolated and 
characterized a cDNA which encoded the carboxyl-terminal fragment of human MPO 
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heavy chain.  Using this cDNA as a probe, they identified a MPO mRNA fragment with 
approximately 3.3 kb in length.  In vitro translation of this MPO mRNA fragment 
generated a major product, a 74 KDa polypeptide precursor.  The identity of this 
polypeptide precursor was confirmed by co-precipitation with anti-MPO IgG antibody.  
Antibodies specific for MPO light and heavy chains both recognized this polypeptide 
precursor.  These findings further support that MPO is initially synthesized as a single 
polypeptide, and then it is further processed into a light chain and a heavy chain 19.  Later, 
human MPO mRNA was identified by MPO cDNA in human leukemia HL-60 cell.  
Using in situ hybridization, Chang et al. located human MPO gene on chromosome 
17q22-24 20. Other studies also localize MPO gene to a region between 17q11-q21 and 
17q21-q42 21.  Interestingly, in mouse, the corresponding myeloperoxidase gene (mMPO) 
was located on chromosome 1122.   
Sakamaki et al. used northern hybridization and S1 mapping analysis of RNA 
technique to confirm that EPO gene was only expressed in eosinophilic subline but not 
neutrophilic subline or in parental human HL-60 cells 11.  Using human MPO cDNA as a 
probe, the chromosomal gene of human EPO was isolated and studied.  This gene 
contained the genetic information for a polypeptide of 715 amino acids with an estimated 
molecular weight about 81 KDa.  Further, EPO heavy chain and light chain were 
identified at C and N termini of this polypeptide, respectively.  Later, In situ 
hybridization studies indicated that human EPO gene was located on chromosome 
17q23.1 23.  
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The high degree homology of human EPO and human MPO at genomic level 
strongly supports the notion that both genes may originate from the same ancestral gene, 
or from gene duplication and divergent evolution.  
Biochemical Properties of MPO and EPO 
Human myeloperoxidase (MPO, EC 1.11.1.7), a disulfide-linked dimer with two 
light chains and two heavy chains, was purified from human leukocytes by three steps 
including dialysis with a low salt buffer solution, separation by gel filtration 
chromatography and carboxymethylcellulose chromatography.  The molecular weight 
(MW) of human MPO was estimated to be 118 kDa by sedimentation equilibrium 
ultracentrifuge 24.  A-Sepharose affinity chromatography was used to purify human MPO 
from peripheral blood from one donor.  The identity of extracted MPO was confirmed by 
having maximum Soret absorbance at 430 nm.  The MW of this human MPO was 
estimated to be 146 KDa 25.  A rapid isolation procedure was applied to purify human 
MPO from normal human leukocyte with about 17% yield.  The high-spin heme signal in 
this purified MPO was demonstrated by electron paramagnetic resonance spectroscopy 
(EPR).  The MW of this purified MPO was determined to be 144 KDa by ultracentrifuge 
26.  A single polypeptide with MW of 80 KDa was identified as primary translation 
product of MPO massager RNA (mRNA).  Thise proMPO is formed by proteolytic 
cleavage and N-linked glycosylation.  After acquisition of heme group, the proMPO 
undergoes a sequential of post-translational modifications to form mature MPO that 
contains a pair of light and heavy chains 27 28.   
Human eosinophil peroxidase (EPO, EC 1.11.1.7), a monomer with one light 
chain and one heavy chain, was purified from eosinophilic leukemia cells by gel filtration 
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and ion-exchange chromatography.  The MW of EPO was determined by gel 
chromatography and estimated to be 77 KDa.  Sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) analysis revealed that this reduced EPO was composed 
of one heavy chain and one light chain with MW of 52 KDa and 15 KDa, respectively 29.  
Later, EPO was purified from normal leukocytes and also demonstrated similar molecular 
weight of 72±1 KDa.  Other analysis revealed this isolated EPO was composed by heavy 
chain and light chain with MW of 58 and 14 KDa, respectively 30.  Similar high spin EPR 
signal of heme group was also observed in purified EPO 31.  Radioimmunoassay revealed 
that the content of EPO was estimated to be 15.0 μg/10 6eosinophils 29.  Carbon 14 
labeled leucine was used as a probe to study the biosynthesis of EPO in marrow cells 
from patients with eosinophilia.  Two EPO precursors with MW of 78 and 72 KDa were 
detected and recognized by anti-EPO antibody.  Monensin, an inhibitor of MPO synthesis, 
did not block the biosynthesis of EPO 32.   
The major Soret band of oxidized MPO is observed at 430 nm and shifted to 470 
nm after reduction 25.  However, the major Soret band of purified EPO is observed at 412 
nm 31.  The unique distorted porphyrin ring structure and positive charged sulfonium ion 
was observed in MPO.  This distinctive structure of MPO is proposed to be the cause of 
red shift of Soret band, and its distinct affinity for chloride.  In site directed mutagenesis 
studies indicate that the Soret band of MPO will shift back to 411 nm when the Met243 is 
replaced by either of Thr, Gln or Val.  The affinity for chloride is also decreased 100 fold 
due to the replacement of Met243 in MPO 33.   
Colorimetric assays are developed to determine peroxidase activity in biological 
matrices.  MPO can specifically utilize chloride and hydrogen peroxide to oxidize 
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chromogen like tetramethylbenzidine (TMB) at pH 5.0 in the presence of resorcinol, an 
EPO inhibitor 34, 35.  Other chromogens were used to measure MPO activity including 
guaiacol, taurine and o-dianisidine dihydrochloride35-37.  Unlike MPO, EPO oxidizes 
bromide instead of chloride under physiological conditions to generate hypobromous acid 
and its conjugate base hypobromite (HOBr/ OBr-) 38.  EPO activity can be determined by 
adding o-phenylene diamine at pH 8.0 in the presence of 3 mM bromide and 1 mM 
hydrogen peroxide 34, 39.  In all these approaches, measured peroxidase activity is 
significantly affected by pH, the presence of peroxidase inhibitor, and the concentration 
of chloride, hydrogen peroxide.   
Immunochemical study indicates that the structure of EPO is distinct from that of 
MPO.  Antibodies that recognize human EPO do not cross react with human MPO, and 
vice versa 32.   
1.2 Catalytic Sites of MPO and EPO 
Both MPO and EPO contain heme groups.  The heme group contains an iron ion 
(ferric oxidation state, Fe3+) at the center of protoporphyrin IX group.  The ferric ion is 
bound to four pyrrole nitrogen.  The fifth coordination position is connected with a 
histidine residue to form an imidazole side chain.  The sixth position is believed to be 
empty at the distal side of both native MPO and EPO.  However, in MPO, histidine 95 at 
distal side may perform as an acid/base catalyst to assist peroxidase catalyzed oxidation 
40, 41. 
Low resolution X-ray crystallography (3 Å) study indicates that heme prosthetic 
group of human MPO contains a bound calcium ion and three asparagine-linked 
glycosylation.  Around the heme prosthetic group, His336 is linked to the heme iron ion 
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on the proximal side of the heme in human MPO.  Simultaneously, His336 is linked to 
Asn421 through a hydrogen bond 42.  Later, Fiedler et al. elucidated human MPO crystal 
structure at higher resolution (1.8 Å) and demonstrated that the methyl groups on the 
pyrrole rings A and C were covalently attached to the carboxyl groups of Glu242 and 
Asp94, respectively, via ester bonds.  The beta carbon of the vinyl group on pyrrole ring 
A connects with the sulfur atom of Met243 to form a sulfonium ion linkage via a covalent 
bond.  Although the pyrrole ring B and D are still co-planar, ring A and C are bent to the 
distal side.  In addition, each side chain of Gln91, His95 and Arg239 connects with one 
immobilized water molecule via a hydrogen bond. These three amino acids side chains 
and the water molecules provide a solvent accessible environment and facilitate the 
oxidation inside the catalytic site 43. A similar covalent attachment in human EPO has 
been identified.  Glu241 is covalently attached with the pyrrole ring via an ester bond.  
However, there is no sulfonium ion linkage in human EPO structure 44. 
During the inflammation, MPO/EPO are secreted by activated leukocytes and 
implicated in host defense. They play an essential role in oxidizing chloride (Cl-), 
bromide (Br-), iodide (I-), and the thiocyanate (SCN-) to form strong oxidants that kill 
microorganism as part of the defense function 7, 17, 45-47.  Three major intermediates, the 
native state of MPO or EPO, Compound I and II are found to catalyze the generation of 
these reactive oxidants,  40, 48, 49.  Each intermediate has its unique structure and spectral 
property.  Electron paramagnetic resonance (EPR) studies indicate the existence of a 
ferryl/prophrin radical (Por˙+ FeIV=O) structure in MPO compound I (Cpd I) 41.  Raman 
resonance spectroscopy studies confirm the presence of oxyferryl (FeIV=O) structure in 
MPO compound II (CpdII) 40   
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The structures of these intermediates and related reactions have been investigated 
to understand the fundamental mechanism of peroxidase catalyzed oxidation.  In the first 
step of the catalytic cycle, H2O2 oxidizes native ferric form of MPO or EPO to 
corresponding active state Cpd I by transferring two electrons and generating water 
(Eq.1).  Other in vitro studies indicate that other hydroxyperoxides like hypochlorous 
acid (chloride-free media) can also oxidize native peroxidase to Compound I (Cpd I).  
The reduction potential of Cpd I is about -1.1 V 50, 51. 
PorFe3+ + H2O2  ?        Por˙+FeIV=O + H2O Eq.1 
 
In the presence of endogenous one-electron donors like nitrite (NO2-), nitric oxide 
(NO•) and tyrosine, Compound I can be quickly reduced to Compound II (Eq. 2), and 
then further to the native ferric enzyme (Eq. 3) via obtaining two sequential one-electron 
and generating nitro dioxide and tyrosyl radicals respectively 50, 52-54.  However, in the 
presence of halides and thiocyanide (SCN-), compound I (Por˙+ FeIV=O) coverts to the 
native form (Pro Fe3+) by obtaining two-electron reduction and generating the 
corresponding hypohalous acid (Eq. 4).  
                        ˙+PorFeIV=O + R ?   PorFeIV=O + R˙ Eq. 2 
                           PorFeIV=O + RH + H+ ?   PorFe3+  + R˙ +˙ H2O Eq. 3 
                        ˙+PorFeIV=O + X- +H+ ?   PorFeI3+ + HOX Eq. 4 
    R= NO•, NO2-, Tyr, X= SCN-, Cl-, Br and I- 
In addition, researchers also propose the reactive species like H2O2, superoxide 
can reduce native MPO to a ferrous intermediate (MPO-Fe2+).  An inactive state, 
Compound III (Cpd III, MPO-Fe 2+-O2) was formed via the binding between MPO-Fe 3+ 
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and superoxide or MPO-Fe 2+ with oxygen, respectively 55-58.  It takes longer time for 
Cpd III to be converted back to the native enzyme form which utilizes two H2O2 
molecules and generate of one O2 molecule 56, 59.  Studies support that Cpd III reacts with 
H2O2/ O2˙ to re-enter classical peroxidase cycle via Cpd II or native MPO 57, 60.  Using 
distinct spectroscopic measurement, our lab reported that both ferric (Fe 3+) and ferrous 
(Fe 2+) MPO could reversibly bind to nitric oxide and generated stable low-spin six-
coordinate complexes Fe 3+ –NO and Fe 2+ –NO, respectively 51. 
The scheme of catalytic cycles include three major pathways: (A) the conversions 
of native ferric peroxidase (MPO) via Compound I, Compound II and back to the native 
state of MPO; (B) the reaction of MPO (Fe 3+) with superoxide or MPO (Fe 2+) with 
oxygen to generate compound III; (C) the reaction of MPO (Fe 3+) or MPO (Fe 2+) with 
nitric oxide (Figure 1.1). Under certain condition, these reactions can be carried in the 
opposite direction.  Overall, the catalytic cycle of peroxidase starts with the conversion of 
native enzyme to its active form Compound I by losing two electrons. Compound I can 
be reduced to the native state (Fe3+) either by two-electron reduction or two sequential 
one-electron reductions.  
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Figure 1. 1  Catalytic Cycles of MPO 
The proposed MPO catalytic model: (A) Native MPO is converted to active MPO 
Compound I (Cpd I) by losing two electrons. Compound I can be reduced to the native 
state (Fe3+) either by two-electron reduction or to compound II (Cpd II) by a one-electron 
reduction. The Compound II is further transformed to the native state via another one-
election reduction; (B) Native MPO (FeIII) or its reduced form MPO (FeII) bind with 
superoxide or oxygen, respectively, to generate an inactive intermediate, compound III 
(Cpd III); (C)  Native MPO (FeIII) or its reduced form MPO (FeII) bind with nitric oxide 
to form MPO (FeIII)-NO or MPO (FeII)-NO, respectively. 
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1.3 Peroxidases and Diseases 
Both EPO and MPO are able to generate cytotoxic oxidants and cause the damage 
of invading pathogens. However, these reactive oxidants may also associate with host 
damage. Upon stimulation, eosinophils and neutrophils are recruited to the sites of 
inflammation and release their unique granule proteins EPO and MPO, respectively.  
EPO and MPO utilize H2O2 and available substrates to initiate a cascade of oxidative 
events.  In vitro studies demonstrate that MPO/EPO-H2O2-X- system are toxic to both 
gram-negative and gram-positive bacteria 47, 61, 62.  The EPO-H2O2-X- system is capable 
of killing parasites like Schistosoma Mansoni 63.  The primary mechanism for EPO/MPO 
to promote microbicidal function is based on the peroxidase catalyzed oxidative damage 
to the pathogen.  Microorganism like Schistosomula remains viable when it incubates 
with EPO alone.  The microbicidal function of peroxidase can be accomplished only in 
the presence of hydrogen peroxide and halide 46, 63, 64.  The cell injury can be inhibited by 
adding heme-enzyme inhibitor, azide, which supports the catalytic role of the heme group 
in the peroxidase 47.  
The contribution of peroxidases in host defense has been questioned since the 
majority of peroxidase-deficient subjects rarely suffer any severe infectious diseases. 
Several reasons may attribute this scenario. First, most of these individuals only lost one 
particular peroxidase activity, either MPO or EPO but not both 65, 66.  The other 
peroxidase-dependent or peroxidase-independent oxidants generation, may compensate 
the loss of one particular peroxidase. In one unique case, a patient was both MPO and 
EPO deficienct. He did suffere severe cor pulmonale disorder and one of his lungs was 
completely damaged by the bacteria attack 67. Second, infectious diseases like Candida 
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are predominately seen in MPO deficient patients with diabetes mellitus 68.  Utilizing 
GC/MS and LC/MS/MS, Brennan et al investigated the potential pathways that 
participate the generation of 3-nitrotyrosine generation in vivo.  Within multiple 
inflammation models, the formation of 3-nitrotyrosine were evaluated in EPO or MPO 
wild type and knockout mice.  In some models, MPO or EPO played a dominant role, 
accounting for the majority of nitrotyrosine generation.  However, in other leukocyte-rich 
acute inflammatory models, no significant protein-bound nitration was observed 69.  
Overall, peroxidase does play an important role in host defense against bacteria, fungi 
and parasites infection. 
Other than the beneficial effects of peroxidases in host defense, more and more 
evidence indicates that peroxidase catalyzed oxidation may lead to host damage.  Recent 
studies indicate that eosinophils and eosinophil peroxidase may involve in the 
pathogenesis of allergic respiratory diseases like asthma, rhinosinusitis by promoting 
oxidative modification 9, 70, 71. 
Asthma, a common lung disorder in developed countries, is characterized by 
wheezing, breathlessness, chest tightness and coughing with reversible airway 
obstruction. In 1998, an estimate of 17 millions Americans suffered from this lung 
disorder.  In addition, 30% of these patients were children 72.  Similarly, rhinosinusitis is 
an inflammation disease characterized by nasal congestion, itching, sneezing and nasal 
discharge.  In 2001, an estimate of 58 millions Americans suffered rhinosinusitis 73.  The 
overall direct cost of asthma and chronic rhinosinusitis is estimated over $ 10 billion per 
year 72, 74.  
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Eosinophil infiltration and activation are associated with airway allergic responses.  
First, eosinophilia is predominately observed in asthma and rhinosinusitis patients.  
Significantly elevated eosinophils were observed in peripheral blood, and sputum 
recovered from asthmatic patients 70, 71, 75  In rhinosinusitis patients, even if they had 
negative skin response, elevated eosinophils were detected in peripheral blood and in 
nasal lavage fluids (NLF) 12, 76.  It is still not clear whether this eosinophilia in patients 
who suffer respiratory disorder just an epi-phenomenon of allergic disease or a 
representation of the involvement of eosinophil in the inflammation response.  A house 
mite allergen challenge study was performed in asthmatic subjects and healthy controls.  
Bronchoalveolar lavage (BAL) was collected 6 hours after allergen challenge.  
Significantly elevated eosinophils recovered from BAL fluid were observed in asthmatic 
patients compared to that in the healthy controls in response to the allergen challenge.  
This finding supports that eosinophils are actively recruited to the lung as a consequence 
of allergen provocation 13. 
In response to cytokine and chemokine stimulation, eosinophils release bioactive 
molecules, generate reactive species and initiate oxidative modification.  Eosinophils are 
recruited to the inflammation sites and release eosinophil specific granule proteins in 
response to chemokines stimulation 77, 78.  Chemokines cooperate with cytokines to 
stimulate eosinophil differentiation, activate cellular response and amplify the immune 
responses 78-80.  Activated eosinophils releases unique granule proteins including 
eosinophil cationic protein (ECP), eosinophil peroxidase (EPO) and major basic protein 
(MBP), and stimulates peripheral mast cell to release histamine 81, 82.  Further, isolated 
MBP activates neutrophils, basophils and mast cells 83, 84.  In addition, activated 
 13
eosinophils release lipids mediator including PAF, LTC4/D4/E4 85-87.  These bioactive 
lipids initiate the allergic response by contracting smooth muscle, increasing mucous 
secretion and facilitating granulocytes migration. The details and references are tabulated 
in Table 1.1. 
Peroxidases are the principle enzymes that generate reactive species in allergic 
diseases like asthma and rhinosinusitis.  In the presence of hydrogen peroxide and 
physiological halide, EPO but not other eosinophil basic granule proteins can cause 
human lung injuries halides 46.  Eosinophil peroxidase can specifically oxidize bromide 
even in the presence of 1000 fold higher chloride condition 38.  In aeroallergen lung 
challenge model, compared to peroxynitrite catalyzed tyrosine nitration, EPO- H2O2-
NO2- system is more efficient in generating nitrotyrosine in vivo.  After allergen challenge, 
70% elevated 3-nitrotyroine in EPO+/+ animal is originated from EPO-H2O2-NO2- 69.  
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 Table 1.1  Bioactive Molecules Detected in Asthmatic Patients 
 
Chemokines Abbreviation Reference 
Regulated upon Activation Normal T-cell 
Expressed and Secreted 
Macrophage Inflammatory Protein-1α 
Interleukin-8 
RANTES 
 
MIP-1α 
IL-8 
70, 77, 78, 88-90 
Cytokines   
Tumor Necrosis Factor-alpha  
Tumor Necrosis Factor-beta 
TNF-α, 
TNF -β 
15, 89, 91 
Interleukin-3 
Interleukin-5 
Granulocyte-macrophage Colony-
stimulating Factor 
IL-3, 
IL-5, 
GM-CSF 
78-80, 92-94 
Platelet-derived Growth Factor-β  
Vascular Endothelial Growth Factor 
PDGF-β 
VEGF 
95, 96 
Granule Cationic Proteins   
Eosinophil Cationic Protein 
Eosinophil Derived Neurotoxin 
Eosinophil Peroxidase 
Major Basic Protein 
ECP 
EDN 
EPO 
MBP 
9, 76, 81-84, 97-99 
Lipid mediators   
Leukotriene-C4/ D4/ E4 
Platelet Activating Factor 
Prostaglandin E2 
LTC4/ D4/ E4 
PAF 
PGE2 
15, 70, 85-87, 100, 101 
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 Aromatic amino acid like tyrosine is readily oxidized by peroxidase by losing the 
phenolic hydrogen and one electron to form tyrosyl radical (Y˙) 102.  Tyrosyl radical is 
relative stable since the radical delocalize around the aromatic ring.  The tyrosyl radical 
reacts with free or protein bound tyrosyl residue to form dityrosine.  EPO and MPO 
utilize hydrogen peroxide and various physiological substrates to generate corresponding 
reactive bromating species (RBS), reactive chlorinating species (RCS), and reactive 
nitrogen species (RNS) species, catalyze oxidative modification and participate airway 
remodeling 2, 103-105 (Figure 1.2). 
Peroxidase catalyzed oxidative modification is proposed to implicate in the 
pathogenesis of respiratory disease like asthma and rhinosinusitis.  Several clinical 
studies support that the release of EPO during inflammation response results in extensive 
oxidation.  After a localized allergen challenge, 3-bromotyrosine content recovered from 
BAL was increased 10-fold, but there were only two- to threefold increases in 3-
chlorotyrosine in the mild asthmatics 104.  Aldridge et al. found that protein-bound 3-
Bromotyrosine, recovered in sputum from asthmatic patients, was significantly elevated. 
The levels of this bromination product correlated highly positively with eosinophil 
peroxidase protein mass (r = 0.79, p< 0.0001) 106.  In addition, 10-fold increase in 
protein-bound 3-nitrotyrosine, and 100-fold increase in protein bound 3-bromotyrosine 
were recovered from BAL of severe asthmatics compared to that from healthy control 107.  
Indeed, peroxidase catalyzed oxidation is implicated in promoting oxidative tissue 
modification in allergic respiratory diseases. 
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Figure 1. 2  Potential Enzymatic Pathways for Generating Reactive Oxidants and 
Oxidation Products 
Each reactive oxidant may result oxidative damage and contribute inflammatory 
injury.  NOS NO synthase, iNOS inducible NO synthase, M2+, redox-active metal ion, Pr 
(M2+), protein-bound redox-active metal ion, L-Arg, L-Arginine.   
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CHAPTER II  
METHODS FOR ANALYSIS OF OXIDIZED TYROSINE SPECIES 
 
 
Peroxidase catalyzed oxidative modifications are implicated in various 
physiological and pathological processing like aging, allergic response and 
neurodegenerative disorders 1-3.  Both in vitro and in vivo studies support reactive 
intermediates generated by MPO/EPO reacting with a variety of targets including protein, 
lipid and genetic materials 4-9.  It is extremely important to understand the operational 
mechanisms of peroxidase induced oxidation because it may not only provide 
information on the involvement of oxidative modification in disease development, but 
may also offer insights into possible strategies to slow or stop oxidative modification.   
Reliable analytical techniques are needed to detect and quantify those reactive 
species including reactive brominating species (RBS), reactive chlorinating species 
(RCS) and reactive nitrogen species (RNS).  However, it is extreme challenges to 
monitor the generation and reaction of these reactive intermediates in vivo due to the 
transient nature of these reactive intermediates. As an alternative approach, most studies  
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are focused  on detecting and quantifying stable end-products of each distinct oxidative 
pathway from normal and pathological specimens4-9.  Protein oxidation has been 
intensively investigated since the last decade due to the following reasons: (1) protein is 
the major scavenger of oxidative free radical species both in intra and extra cellular 
environments 1; (2) protein has a longer half-time compared with other macromolecules 
and may preserve more structural changes 10; (3) the modification on the protein may 
associate with the change of the corresponding enzymatic function and may initiate a 
cascade biological event 1, 11, 12.  Although various amino acid residues are subjected to 
reactive oxygen species attack, aromatic amino acid residues like tyrosine, phenylalanine 
and tryptophan are more vulnerable to free radical induced oxidation 13, 14 For example,  
3-Bromotyrosine can be generated by the reaction of tyrosine with HOBr/OBr- which 
may originate from the EPO/MPO-H2O2-Br- system 15.  3-Chlorotyrosine is the product 
of tyrosine reacting with HOCl/OCl- or with species such as chlorine (Cl2) 16, 17.   
3-Nitrotyrosine is generated when reactive nitrogen species react with free tyrosine or 
tyrosine residue 6, 7, 18.  Dityrosine is formed by radical-radical addition reaction via a 
tyrosyl radical generating system 19, 20.  Hydroxyl radical oxidizes phenylalanine to 
generate non physiologic tyrosine species, m-tyrosine and o-tyrosine 13, 21.  All these 
oxidized tyrosine species resist to change during acid hydrolysis.  Indeed, these oxidized 
tyrosine species are unique molecular fingerprint to study potential the mechanisms of 
protein oxidation. 
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 2.1 Antibody-based Immunostaining and ELISA Assays 
A variety of approaches including immunohistochemical and enzyme-linked 
immunosorbent assay (ELISA) have been developed by using commercially available 
polyclonal and/or monoclonal antibodies to recognize oxidized tyrosine species.  
Antibodies which specifically recognized oxidized tyrosine species including 3-
nitrotyrosine, Dityrosine, 3-chlorotyrosine have been used to detect and localize these 
oxidation markers in vivo 22-27.   
Immunostaining offers a way of localizing oxidized tyrosine species within 
biological matrices 28.  Using 3-nitrotyrosine (3-NO2Y) specific antibody and 
immunohistochemical staining, elevated 3-NO2Y was detected in myocardium from 
patients with myocarditis 23, in atherosclerotic lesions of human coronary arteries 29, 30, in 
the lower neuron from multiple sclerosis patients 31, in Lewy body core from patients 
suffered Alzheimer's disease or Parkinson’s disease 32, 33  and in the lung tissue from 
patients with adult respiratory distress syndrome (ARDS) 34.  Similarly, dityrosine was 
detected in lipofuscin from aged human brain 24.  In the mice endotoxemia model,  
3-Chlorotyrosine was detected in liver tissue and co-localized with neutrophils 27.   
ELISA assay is a powerful tool to evaluate relative amounts of oxidized tyrosine 
species in vivo.  Detection of oxidized tyrosine residue requires minimum sample 
handling procedures including incubation, washing and reaction.  In addition, there is no 
artifact generation during sample processing and the oxidized protein remains intact and 
may use for further investigation.  Using an ELISA assay, 3-nitrotyrosine was only 
detected in plasma from type II diabetic patients (n= 40, 0.251±0.141 μM) 35.  Elevated 
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3-nitrotyrosine (1.27±1.03 μM) was detected in plasma samples from celiac disease 
patients but not in that from controls 36 37.  Recently, several studies reported using 
competitive enzyme-linked immunosorbent assay (c-ELISA) to quantify nitrated protein 
in plasma and other biological fluids 38, 39.  Other studies reported the detection of 3-
nitrotyrosine residue in various matrixes including bovine serum albumin (BSA), human 
serum albumin (HSA), α1-antiprotease inhibitor, pepsinogen and fibrinogen.  To quantify 
nitrated protein, a standard curve was constructed by determining the binding of the anti-
3-NO2Y antibody to the immobilized antigen (nitrated protein) in the presence of a serial 
dilution of nitrated BSA or corresponding nitrated protein solutions (Fig 2.1).  Their 
assay demonstrates the high affinity between 3-NO2Y residue and polyclonal antibody.  
95.8% antibody binding was inhibited by 10 mM of 3-NO2Y but only 3.3% inhibition 
was observed in the presence of the 10 mM of tyrosine.  But the specificity of this assay 
may be challenged due to the extremely low abundance of 3-NO2Y compared with 
tyrosine (3-NO2Y:Y, approximately 0.1-1:106)40.  In addition, the high affinity binding 
between antibody and 3-NO2Y residue may also be altered by the environment of 3-
NO2Y residue, distinct protein structure, sample amount, and other components that may 
cross react with the antibody.  The half maximal inhibition concentration (IC50) values for 
different nitrated protein were varied from 5-100 nM 41.   
 36
 1 2 3 
  
Figure 2. 1  Schematic Diagram of Competitive ELISA  
  Nitrated BSA (immobilized antigen);   nitrated BSA (standard) or nitrated 
protein in sample;   Rabbit anti-nitrotyrosine IgG;   HRP conjugated donkey anti-
rabbit Ig G.  Briefly, the 96-well plate was blocked with nitrated BSA.  A PBS solution 
containing polyclonal rabbit anti-nitrotyrosine Ig G was mixed with variable amount of 
nitrated BSA and incubated with immobilized nitrated BSA.  The rabbit anti-nitrotyrosine 
Ig G was bound with either immobilized nitrated BSA or nitrated BSA in PBS solution.  
After a sequential washing, incubating donkey anti-rabbit Ig G antibody was applied to 
bind with rabbit anti-nitrotyrosine Ig G which was bound with immobilized nitrated BSA. 
After washing, distinct color was developed and detected at 490 nm. 
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However, cross-reactivity and semi-quantitative nature dramatically limits the 
utilization of this technique for quantification purpose 38, 41.  Although the antibodies 
were developed to target a distinct oxidized tyrosine residue, the abilities of these 
antibodies to specifically recognize this unique oxidation product, especially in complex 
biological matrixes, were little tested.  The identity of recognized antigen may be queried 
because there is no direct structural information of this antigen available in the assay.  
Further more, there is no immunochemical assay yet available that can simultaneously 
quantify multiple oxidized tyrosine species and their precursors.  
2.2 Analytical-based Quantitative Assays 
Analytical approaches include sample extraction, separation, and quantification of 
the protein-bound oxidized tyrosine species. High performance liquid chromatography 
(HPLC) and gas chromatography (GC) are commonly used to separate oxidized tyrosine 
species in the protein hydrolysate 2, 8, 15-18, 20, 42-45.  Detection techniques can be selected 
based on the requirement for selectivity, precision and detection limit.  Currently, on-line 
detectors include ultraviolet-visible detector (UV), fluorescence detector, electrochemical 
detection detector (ECD) and mass spectrometer (MS). 
2.2.1 Protein Hydrolysis 
Peroxidase catalyzed oxidation generate both free and protein bound oxidized 
tyrosine species.  To analyzing protein-bound oxidized tyrosine species, protein is 
separated from salts and hydrolyzed into amino acid residues.  Protein was commonly 
hydrolyzed to yield free amino acids under 6 M HCl at 110 ◦C for about 24 hours 46-48.  
Further investigations indicate that tyrosine can be easily nitrated when co-incubate with 
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trace amount of nitrite or nitrate ions in acidic condition at elevated temperature 40, 49.  
Trace amount of nitrite ion (10 μM) induces significant tyrosine nitration (up to 250 fold 
increase).  However, this nitration can be significantly reduced by adding 1% phenol or 
1% butylated hydroxytoluene (BHT) into this acidic system 50, 51.  Similar tyrosine 
chlorination and bromination were noticed in acidic condition in the presence of the 
corresponding anion ions, chloride and bromide, respectively 15, 52. 
Several approaches are carried out to eliminate potential artifacts generation during 
protein hydrolysis.  First, all the glassware should be carefully cleaned to create a clean 
environment (nitrite, nitrate, chloride and bromide free).  The general procedure includes 
rinsing with HPLC grade water, and baking at 500 degree over 12 hours to reduce the 
anions 17, 52.  Second, techniques including dialysis, protein precipitation and strong 
cation ion exchange chromatography, are used to separate protein from water soluble 
salts prior to acidic hydrolysis 52-54.  Third, oxidation scavengers including phenol and 
BHT are added into the system to reduce artifact generation 50.  Finally multiple protein 
hydrolysis techniques are developed to meet individual purpose. For example, 
hydrobromic acid (HBr) or methanesulfonic acid (MSA) instead of hydrochloric acid is 
used to eliminate chloride ion in system 2, 17.  Mild enzymatic digestion in neutral 
condition (pH=7.2) was performed and no artifact was detected 40, 50.  However, the 
potential limitations of enzymatic digestion include low yield of protein hydrolysis and 
the contribution of tyrosine and oxidized tyrosine species from autolysis of protease itself 
49, 50.  Alkaline hydrolysis also demonstrated that no artifact was generated during 
processing.  However, multiple interference peaks of 3-nitrotyrosine were observed and 
additional derivatization step (acidic condition) was required 55.  In addition, the 
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degradation of oxidized tyrosine species was observed during alkaline hydrolysis 56, 57.  
Although these procedures were proved effectively reduced tyrosine residue oxidation 
during hydrolysis, none of these methods can guarantee no artifact generation during 
protein hydrolysis.  To monitor the artifact generation, unique isotope labeled tyrosine 
species (13C9, 15N1 Tyr and 2H4 Tyr respectively) were added prior to protein hydrolysis 
and served as chemical detectors of preparative oxidation 18 55.  Compared to the natural 
abundance tyrosine, the isotope labeled tyrosine species are structurally identical except 
for the extra molecular weight.  During sample preparation, if trace amount anion ions are 
left in the hydrolysis chamber, natural abundance tyrosine (12C9, 14N1 Tyr) and the 
corresponding isotope labeled tyrosine (13C9, 15N1 Tyr or 2H4 Tyr) will be oxidized at the 
same reaction rate to generate distinct oxidation products which can be distinguished by 
the mass spectrometer only 18, 52, 55.  In deed, isotope labeled tyrosine serves as an internal 
quality controller for potential ex vivo oxidized tyrosine generation to insure that the final 
result only represents oxidation stress in vivo. 
2.2.2 Sample Purification and Derivatization 
Due to the complexity of biological matrixes, purification and derivatization are 
essential steps for quantification of free or protein-bound tyrosine species.  Purification is 
used to remove extra acid, salt and unwanted debris from biological matrix.  
Derivatization is a critical step that can modify the structure of analyte to get better 
separation and sensitivity.  
Protein precipitation (PPT), liquid-liquid extraction (LLE) and solid phase 
extraction (SPE) are commonly used to desalt and to remove macromolecules and 
potential interference substances.  Organic solvents like acetonitrile, chloroform, 
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methanol and diethyl ether were used to isolate protein in tissue homogenate, plasma, and 
other biological fluids 18, 40, 52, 55.  Protein dissolves in solvent with large dielectric 
constant like water.  Organic solvents with smaller dielectric constant, like acetonitrile 
and methanol, significantly decrease protein solubility and induce protein precipitation 58.  
The smaller the dielectric constant of the final solution, the lower solubility of the protein 
will be.  In addition, decreased temperature also facilitates protein precipitation.  Protein 
pellet is obtained by centrifuging at 4000~9000 g 55 18.  The supernatant (for free amino 
acid) or protein pellet (for protein bound amino acid residue) are recovered. 
Liquid-liquid extraction (LLE) is a powerful tool to separate an analyte from a 
mixture or to remove unwanted interference compounds.  The separation is achieved 
based on the difference in solubility of the analyte in two immiscible liquid phases 
(aqueous phase and organic phase).  The more hydrophobic of the analyte, the better 
extraction efficiency is achieved by LLE.  Extracted analyte is easily recovered by 
separating the liquid layer.  The extraction efficiency of analyte (E) is determined by 
equation 2.1: 
 
E = 2.1
KD V
1 +KD V
 
 
KD is the partition coefficient of the analyte in the organic and aqueous phases (Co/Caq); 
V is the volume ratio of two phases (Vo/Vaq).  To get better extraction efficiency, the 
organic solvent is selected with bigger KD value and larger volume.  Successive multiple 
extractions give a better recovery.  Using chloroform as the extraction reagent, about 
93% of the free dityrosine was extracted from cerebrospinal fluid 59.  Other reagents like 
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mixture of chloroform/methanol (v:v, 2:1) were used to extract 3-nitrotyrosine from 
human plasma 55.   
Solid phase extraction (SPE) is commonly used to remove water soluble strong 
acid/base.  The 3 mL SPE cartridge with 100-500 mg packing material was commonly 
used.  The packing material of SPE column is often in irregular shape with diameters 
above 50 μm (10-20 fold larger than HPLC packing material).  The separation 
mechanism of SPE is similar to that of HPLC column.  First the analyte is loaded on a 
pre-conditioned cartridge.  The analytes and unwanted debris are separated by choosing 
appropriate washing and eluting solvents.  The eluted analytes are analyzed directly or 
dried under vacuum and then reconstituted prior to quantitation.  Compared with LLE, 
SPE demonstrates a better separation of analyte from interferences, easier collection of 
analyte fraction and less organic solvent usage.  In addition, automation can easily be 
adapted using SPE column.  Different adsorbents, extraction mechanism were 
investigated to improve the recovery and eliminate interference peak of analytes in 
different matrices.  In addition, different washing, elution solvents were compared.  
Reverse phase C-18 SPE column is one of the commonly used cartridges to remove 
excess acid and potential debris in protein hydrolysate 6, 17, 18, 43, 45, 52, 60.  Further 
purification is achieved by using additional chrom P cartridge right after C-18 SPE 
extraction 61.  Frost et al used a polymeric resin based ENV+ cartridge to remove 
interference of 3-nitrotyrosine 55.  Anion exchange column (AG1-XS8) was used to 
purify 3-nitrotyroisne in protein hydrolysate 62.  Tandem octadecylsilyl and 
aminopropylsilyl cartridges were applied to isolate tyrosine and nitrotyrosine respectively 
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in protein hydrolysate 63.  Aminopropyl cartridge was used to isolate dityrosine, ortho-
tyrosine and nitrotyrosine in cat urine 64.   
Derivatization is a method of chemically transforming the analyte into a new 
compound which has different volatility, thermo-stability and better chromatographic 
behavior to fit the requirement of quantitation 65.  For GC based assay, the derivatization 
step is an essential step to eliminate the presence of polar group like OH, NH2 and 
COOH.  The carboxylic acid group (COOH) of tyrosine and oxidized tyrosine are 
converted to the corresponding ester derivative by reacting with 1-propanol at acidic 
condition (HCl or HBr) at 65 ◦C for 20~ 30 minutes 2, 52.  The resulting solutions further 
react with heptafluorobutyric anhydride (HFBA), pentafluoropropionic anhydride (PFPA) 
and trifluoroacetic anhydride (TFAA) in the presence of ethyl acetate 52 2, 51.  N-(t-butyl-
dimethylsilyl)-N-methyltrifluoroacetamide chlorosilane (TBDMS) was used to protect 
hydroxyl group to form an ether derivative 55.  However several steps including 
acetylation, o-deacetylation and reduction were required to achieve a better separation 
and lower detection limit 40.  The complexity of derivatization procedures may introduce 
potential artifacts generation, especially under acidic conditions 49.  Chemical 
derivatization of analyte prior to HPLC system gave a lower detection limit and better 
chromatographic behavior.  Butylation of o-tyrosine and nitrotyrosine dramatically 
improved their sensitivity.  MS response of o-tyrosine and nitrotyrosine were increased 7 
and 6 fold respectively.  However, butylation of o,o'-dityrosine did not improve the 
sensitivity due to the side reactions.  The limit of quantitation (LOQ) of NO2-Tyr butyl 
ester, o-Tyr butyl ester, and di-Tyr in cat urine samples were reported at 14.5, 28.2 and 
140.9 nM, respectively 64.   
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2.3 HPLC with on-line Ultraviolet-visible and Fluorescence Detector 
HPLC is a common technique for separation.  A number of LC detectors including 
ultraviolet-visible (UV), fluorescence detector, electrochemical detector (ECD) and mass 
spectrometer (MS) are developed to accomplish different requirements.  Both UV and 
fluorescence detectors have been used to quantify free oxidized tyrosine species based on 
specific absorbance at acidic or basic condition.   
Using an UV detector, Kaur et al. detected 3-nitrotyrosine in serum and synovial 
fluid from rheumatoid arthritis patients but not in that from controls.  Later, this method 
was adopted to determine plasma level 3-nitrotyrosine in chronic renal failure patients 66.  
A higher plasma level of 3-nitrotyrosine was detected in patients with septic shock (173.9 
μM) than those without shock (75.6 μM).  In addition, no 3-nitrotyrosine was detected in 
control plasma.  The detection limits were reported to be 0.2 -0.6 μM 66, 67.  Protein-
bound nitrotyrosine was detected based on its characteristic spectral absorbance in 
alkaline or acidic solutions.  After treated with peroxynitrite or tetranitromethane, 
oxidized bovine Cu-Zn superoxide dismutase have a maxima absorbance at 438 nm in 
basic solution (pH 9.5) and a secondary peak at 356 nm in acidic condition (pH 3.5) 7.  
After exposure to a 100-fold molar excess of peroxintirite, glutathione reductase also 
exhibits absorbance at approximately 423 nm, indicating the presence of 3-Nitrotyrosine 
residue 68.  Using HPLC with online UV detector (280 nm, pH=2.5), Wu et al reported 
the generation of 3-bromotyrosine and 3,5-dibromotyrosine by incubating HOBr or N-
bromo, or N,N-dibromoamine with 2 mM tyrosine solution 15. 
Using pre-column derivatization techniques, the amino groups of 3-nitrotyrosine or 
dityrosine are reacted with fluorescence active compounds including 7-fluoro-4-
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nitrobenzo-2-oxa-1, 3-diazole, o-phthalaldehyde and 4'-Dimethylaminoazobenzene-4-
sulfonyl chloride.  The derivatized tyrosine species can be detected by the fluorescence 
detector 69, 70.  The detection limits of these assays were reported at 0.1-1 pmol level.  
Compared to the UV detection, fluorescence detection has lower background, better the 
sensitivity and selectivity.  But these two approaches are limited for identification of any 
ex vivo generated trace level oxidized tyrosine species during sample preparation.   
2.4 HPLC with On-line Electrochemical Detector 
Electrochemical detector (ECD) was widely applied to detect and quantified 3-
nitrotyrosine 71, 72, 3- Chlorotyrosine 73, dityrosine 74, meta- and ortho-tyrosine 75, 76.  A 
better selectivity and lower detection limit is achieved by combining HPLC separation 
system and sensitive electrochemical detector.   
Using HPLC-ECD system, 3-nitrotyrosine was detected by passing through 
reduction potential and then following oxidation potential.  Elevated plasma level 3-
nitrotyrosine was observed after lipopolysaccharide (LPS) administration 71.  Hensley et 
al reported an assay using ECD detector to quantify tyrosine, 3-nitrotyrosine and 3,4-
dihydroxyphenylalanine (3,4-Dopa) simultaneously 77. Later, they observed elevated 
dityrosine and 3-nitrotyrosine in the hippocampus and neocortical regions of the brain 
and ventricular cerebrospinal fluid form Alzheimer patient compared to that from healthy 
control 72.   
To achieve a lower detection limit, 3-nitrotyrosine was modified to N-acetyl-
amino-tyrosine before loading HPLC-ECD system.  The separation was significantly 
improved after 3-nitrotyrosine acetylation, o-deacetylation and reduction.  In addition, the 
detection limit was reported at 20 fmol 40, 50.  Other assays used ECD detector to quantify 
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3-chlorotyrosine, dityrosine, meta-tyrosine and ortho-tyrosine generated in vitro and in 
vivo 73-76.   
2.5 Mass Spectrometry-based Assay 
Mass spectrometry (MS) is a powerful analytical technique that is widely used for 
identification, quantitation and clarification of structural properties of interested 
analyte(s).  Mass spectrometer is divided into three major parts: ionization chamber (ion 
source), ion analyzer and detector (Fig 2.2).  Once the sample is introduced into an 
ionization chamber, the gas phase cation or anion ions are generated.  The resulting ions 
are separated in the mass analyzer according to their mass charge ratio (m/z).  Once the 
ion which contains selected m/z ratio reaches the detector, an electronic signal will be 
generated and recorded by the data system.  Compared with other LC detector, mass 
spectrometer is more expensive, less user friendly. But unique selectivity and sensitivity 
of mass spectrometry offer an ability to quickly detect and quantify interested compound 
which only require minimal sample preparation, even for complex biological matrix like 
tissue homogenate, plasma etc78.  
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Figure 2. 2  Schematic Diagram of Mass Spectrometer  
Analytes are introduced into ionization chamber by several separation techniques 
including gas chromatography (GC), liquid chromatography (LC), and capillary 
electrophoresis (CE).  Once cation (positive) or anion (negative) ions were generated in 
ionization chamber, these ions were transported into ion analyzer and sorted according 
their m/z ratios. Only the ion with correct m/z ratio can pass through the ion analyzer and 
reach the detector. 
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Various ionization techniques, including electron impact (EI), chemical ionization 
(CI), negative-ion chemical ionization (NICI) electrospray ionization (ESI) and 
atmospheric pressure chemical ionization (APCI), may be used to detect and quantify 
biomarkers like oxidized tyrosine species 62, 79-83.  In electron impact (EI) ionization 
mode, the high-energy electron (~70 ev) is generate from electrically heated filament. 
Then the high-energy electrons collide with gas phase analyte.  One electron from neutral 
molecule (A) is knocked out, and the positive charge ion (A+) is generated.  This 
ionization process may generate either molecular ion (A+) or fragment ions (B+ or C+) 
dependent on applied electron energy, source temperature and the structure of the analyte, 
(Equation 2.2).   
A  +  e  ? A+  +  2e 
A  +  e ? B+  +  C+ +  3e                               (Eq.2.2) 
Later chemical ionization (CI), a softer ionization technique, was adopted for 
quantitation of 3-nitrotyrosine.  The CI technique starts with reagent gas being ionized by 
electron impact ionization.  Then the electronic charge is transferred from reagent gas ion 
to the gas phase analyte molecule through ion-molecule reaction to generate analyte ion.  
Negative-ion chemical ionization (NICI) is similar to CI technique. However, the reagent 
gas serves as the buffer gas to slow down the high-energy electrons so that some 
electrons have just the right energy to be captured by analyte molecules.   
Atmospheric pressure ionization (API), the ionization technique that occurs under 
atmospheric pressure (760 mm Hg), includes electrospray ionization (ESI), atmospheric 
pressure chemical ionization (APCI) and atmospheric pressure photo ionization (APPI).  
The first two ionization techniques, ESI and APCI, are more commonly used in detection 
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and quantitation of polar molecules like oxidized tyrosine species 84.  In electrospray 
ionization (ESI), analyte solution is pushed through a narrow charged capillary interface 
and sprayed as very fine mist of charged droplets.  Warm high purity nitrogen flow is 
commonly used to facilitate liquid evaporation.  As a consequence of evaporation, the 
droplet surface charge density is increased.  A phenomenon referred as Coulombic 
Fission is occurred and the gas phase ion is generated.  ESI works well for polar, charged 
compounds with small and large molecular weights.  Multiple charge ions are commonly 
observed in ESI spectrum.  Atmospheric pressure chemical ionization (APCI) is more 
frequently used to anlayze less-polar compound.  The sample solution is heated and 
sprayed with high flow rate nitrogen to form aerosol mist.  The corona discharge needle 
is used to ionize the analyte.  Compared with ESI, APCI is essentially a gas-phase 
ionization technique.  
Numerous of mass analyzers are developed to accommodate the requirements on 
mass range, accuracy and precision.  Magnetic sector mass spectrometer (double-
focusing mass spectrometer) provides high sensitivity and resolution by separating of 
ions based on their passages through the perpendicular electric and magnetic fields.  
Time-of-flight (TOF) mass spectrometer measures the time that is required for the 
accelerate analyte ions to pass through a constant length tube.  It provides a moderate 
mass resolution over a larger mass range. Ion trap mass spectrometer retains ions into a 
small region (ion trap) between a ring electrode and two end cap electrodes by specific 
oscillating electronic field.  By changing the potential on the end caps, the ions within a 
specific m/z range can be trapped in or ejected out of the ion trap.  Ion trap mass 
spectrometer is widely used because of its ability of performing a sequential MS/MS 
 49
reaction modes to provide valuable structure information 85.  However, Quadrupole mass 
spectrometer is the most commonly used mass spectrometer for quantitation purpose.  
Quadrupole mass spectrometer contains four parallel cylindrical rods that surround the 
ion paths.  Radio-frequency (RF) voltage and direct current (DC) voltage are applied on 
the quadrupole rods to permit the ion with particular m/z ratio passing through this 
electronic field.  Only the selected ion with specific m/z ratio has a stable trajectory and 
reaches the detector.  Other ions with different m/z ratios have unstable oscillations that 
increase in amplitude until they collide with quadrupole rods 86 87.  
As mentioned previously, both single and triple quadrupole mass spectrometers are 
widely used for quantitation of oxidized tyrosine species.  A schematic diagram of a 
typical triple quadrupole mass spectrometer is presented in figure 2.3.  A triple 
quadrupole mass spectrometer includes of three quadrupoles.  The system includes two 
mass filters (the first and third quadrupole, Q1 and Q3 respectively) and a collision cell 
(the second quadrupole, Q2).  Triple quadrupole can be operated in different modes 
including Q1 scan (Q1), single ion monitoring (SIM), parent ion scan, daughter ion scan, 
neutral loss and multiple reaction monitoring (MRM) to accommodate analysis 
requirement.  In Q1 scan (Q1), Q1 is set at a scan mode, which allows Q1 to filter one m/z 
each time sequentially. For triple quadrupole, both Q2 and Q3 are set at standby mode and 
there is no collision-activated dissociation (CAD) gas present in Q2. Thereby the ion 
passes through Q2 and Q3 directly and reach detector to generate the corresponding 
signal.  Q1 scan provides the mass spectra in a specific mass range.  Q1 scan is commonly 
used to determine the m/z ratio of molecular ion due to the limitation of low sensitivity.  
In single ion monitoring (SIM) mode, Q1 is set to monitor one target ion with specific 
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m/z ratio and both Q2 and Q3 are set in standby mode. Only ion with specific m/z ratio 
can pass through quadrupole (Q1) and reach the detector.  SIM mode detects and 
quantifies one particular ion, which dramatically improve the sensitivity.  Since only the 
ion with selected m/z ratio can pass through Q1, the background noise is significantly 
decreased.  In parent scan mode, Q1 operates in scanning mode and transmits ion with 
sequential m/z ratio into the collision cell (Q2).  When the ions enter Q2, they collide with 
the neutral CAD gas molecules and generate corresponding fragment ions.  The 
fragmented ions (daughter ions) are then transported to Q3, which is set at SIM mode for 
the daughter ion with particular m/z ratio.  Similarly, in daughter scan mode, Q1 is set at 
SIM mode to isolate one particular ion (parent ion).  After the collision in Q2 cell, the 
corresponding fragmented ions (daughter ions) are transported to Q3.  The Q3 operates in 
scanning mode and filters each distinct m/z ratio successively.  The resulting daughter 
spectrum of the selected parent ion provides valuable structure information.  Daughter 
scan provides potential ion pair transitions that may be used in MRM mode.  Neutral loss 
is applied to identify compounds that lost a specific uncharged group during either a 
rearrangement process or collision induced dissociation (CID).  In neutral loss mode, 
both Q1 and Q3 operate in scanning modes with the particular difference (∆m).  The 
detector responses to the ion that loss (or gain for neutral gain) the selected uncharged 
group (∆m) in Q2.  Multiple reaction monitoring (MRM) is designed to detect and 
quantify a specific analyte in complex matrices.  In MRM mode, both Q1 and Q3 are set 
at SIM mode.  The ion with specific m/z ratio is isolated by Q1 first.  Then this parent ion 
is collided with CAD gas in Q2 cell and generated corresponding daughter ion (s).  Only 
selected daughter ion(s) can pass through Q3 and reach the detector.  Both SIM and MRM 
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mode are widely used in quantitation of oxidized tyrosine species due to their exceptional 
sensitivity.  Compared with SIM mode, MRM is more sensitive and provides better 
specificity.  
In current mass spectrometer, the detector generates electronic current which is 
proportional to the mass abundance of each specific m/z ratio.  Commonly used ion 
detectors include electron multiplier, photomultiplier, Faraday cup and microchannel 
plate detector 87.  
2.6 Analytical Methods of Quantitation of Oxidized Tyrosine Species 
Numerous assays based on gas chromatography with on-line mass spectrometer 
(GC/MS or GC/MS/MS) were developed to analyze oxidized tyrosine level at 
physiological and pathological conditions.  GC/MS offers better separation and higher 
sensitivity.  One limitation of GC/MS technique is that all the analytes has to be the gas 
phase prior to separation and detection.  To analyze polar compounds like oxidized 
tyrosine species by GC/MS system, various chemical derivatization reagents were 
employed to increase analyses’ volatility and ionization efficiency 88 6, 16, 17, 43-45. 
Using GC combined stable isotope dilution mass spectrometry, the detection limit 
of 3-Chlorotyrosine was 50 attomole with coefficients of variance (CV) within 3% 52.  3-
chlorotyrosine was detected in normal aortic intima. The level of 3-chlorotyroisne was 
30-fold higher in LDL isolated from atherosclerotic intima than that from circulating 
LDL 16.  A fully validated GC/MS/MS assay was developed to detect and quantify 3-
nitrotyrosine in human plasma.  The internal standard was purified by HPLC to eliminate 
nitrate and nitrite to avoid artifacts generation during sample preparation.  Using this 
technique, basal level 3-nitrotyrosine was determined in 11 healthy volunteers 89.  
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 Q1 Q3Q2 Detector  
 
 
Mode Q1 Q2 Q3 
Q1 Scan Scan Off Off 
SIM Static Off Off 
Parent Scan Scan Collision Static 
Daughter Scan Static Collision Scan 
Neutral Loss Scan Collision Scan 
 
Figure 2. 3  Schematic Diagram of Typical Triple-quadrupole Mass Spectrometer 
and Its Operation Modes  
Typical triple-quadrupole includes two mass filters Q1 and Q3 and one collision cell 
Q2.  Numerous modes including Q1 san, SIM, parent scan, daughter scan, MRM and 
neutral loss can be achieved by adjusting individual quadrupole setting (detail see table).   
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100-fold elevated dityrosine was observed in LDL isolated atherosclerotic lesions 
compared to the circulating LDL. No similar increase of meta-tyrosine or ortho-tyrosine 
was detected 43.  Dityrosine and ortho-tyrosine were also detected in mouse heart, muscle, 
brain, liver and urine sample 44, 45.  At basal level, 3-bromotyrosine in bronchoalveolar 
lavage (BAL) proteins recovered from mildly allergic asthmatic individuals was slightly 
higher than that from controls.  After a localized allergen challenge, in BAL protein, 3-
bromotyrosine content was increased 10-fold, but only two- to threefold increases in 3-
chlorotyrosine 2.   
In these studies, the accuracy and sensitivity were significantly improved by 
utilizing isotope labeled internal standard (13C labeled or 2H labeled isotopmer) 
combining multiple reaction monitoring mode (MRM), 88, 90.. HPLC with on-line 
electrospray ionization mass spectrometry or tandem mass spectrometry (HPLC/ESI/MS 
or HPLC/ESI/MS/MS) assay has several advantages compared with GC/MS assay.  
Chemical derivatization procedure becomes an optional step to improve sensitivity.  But 
majority LC/MS assay skip this step to eliminate the potential sample loss, contamination 
and side reactions 79.  Sample preparation is dramatically simplified and the efficiency is 
significantly improved 88.   
LC/MS/MS assays for detecting oxidized tyrosine species in different matrices 
were explored.  A simple and sensitive LC/MS/MS assay was used to detect 3-
nitrotyrosine in rat brain tissue. The detection limit was below 10 nM81.  Free 3-
nitrotyrosine, 3-bromotyrosine and 3-chlorotyrosine were detected in plasma from 
healthy volunteers 79.  Yi et al. developed a LC/MS/MS assay to detect and quantify 3-
nitrotyrosine and tyrosine simultaneously. HPLC condition was optimized to detect 3-
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nitrotyrosine even in presence of 100,000-fold higher tyrosine.  The detection limit for 
standard samples was 0.5 pg/μL (s/n>3) with a linear range from 0.5-100 pg/μL 49.  After 
peroxynitrite treatment, 3-nitrotyrosine and 3, 5-dinitrotyrosine were observed in peptides 
like leucine-enkephalin (YGGFL), V3 loop (GPGRAF), and LVV-hemorphin7 
(LVVYPWTQRF) 91.   
Protein bound dityrosine in milk powder was analyzed by LC-ESI/MS/MS.  The 
mean recovery of dityrosine from milk powder was about 90%.  The limit of detection 
(LOD) and limit of quantitation (LOQ) for protein bound dityrosine (diTyr/Tyr) were set 
at 2 μmol/mol and at 6 μmol/mol 92.  
HPLC combined atmospheric pressure chemical ionization-tandem mass 
spectrometry (HPLC-APCI-MS/MS) system was also utilized to detect tyrosine, 
dityrosine, simultaneously.  The linearity of each analyte was larger than 0.98.  The limits 
of quantitation (LOQ) of tyrosine, dityrosine, in human urine sample were 1 μM, 50 nM, 
respectively 82.  
Other applications include detecting plasma level 3-nitrotyrosine and 3-
chlorotyrosine in preterm infants with clinically documented bronchopulmonary 
dysplasia 93  Significantly elevated 3-Bromotyrosine was detected in sputum supernatants 
recovered from mild to moderate asthma compared to that from controls. But no 
significant increase of protein bound 3-chlorotyrosine and carbonyl were observed 
between two groups 94.  Elevated protein bound 3-chlorotyrosine also were recovered 
from tracheal aspirate in low weight infants (n=69) compared to the controls with regular 
weight. In addition, these 3-chlorotyrosine levels were strongly correlated with 
myeloperoxidase activity (r 2= 0.75, p < 0.0001) 95.  Using HPLC-MS/MS, 3-
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chlorotyrosine was detected in HDL recovered from human aortic atherosclerotic lesion 
96.  Also elevated dityrosine was detected by LC/MS in brain of Alzheimer’s disease 
(AD) patients 97.  
2.7 Conclusions 
To further understand the mechanism of EPO/MPO induced oxidative damage both 
in vitro and in vivo, the level of an array of oxidized tyrosine species and their precursors 
need carefully investigate.  GC/MS, LC/MS and LC/MS/MS are highly sensitive and 
specific approaches to study these oxidation products in biological specimens.  Mass 
spectrometer provides specific structure information of each analyte.  Compared to 
antibody based immunochemical assay, mass spectrometry based assay has a better 
sensitivity and specificity.  Overall GC or LC/MS/MS approach is superior to 
immunochemical methods and other chemical detection approaches by providing specific 
structural information, improved sensitivity and simplicity of sample preparation.  
Here we demonstrate the unique character of mass spectrometry based assay to 
quantify multiple oxidized tyrosine species in various biological specimen.  First, it can 
simultaneously detect and quantify six oxidized tyrosine species and the corresponding 
precursors.  As illustrated in figure 1.2, activated eosinophil and neutrophil releases its 
unique granule protein EPO and MPO, respectively.  EPO or MPO utilizes hydrogen 
peroxide and various physiological substrates to generate corresponding reactive 
bromating species (RBS), reactive chlorinating species (RCS), and reactive nitrogen 
species (RNS) species.  These reactive species participate in oxidative modification and 
involve in inflammatory injury.  To study the operational mechanism of EPO and MPO 
catalyzed oxidative modification, multiple oxidative products are investigated to re-
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construct the oxidative damage in vivo.  Other GC/MS and LC/MS assays can only detect 
one or several oxidized tyrosine species.  To obtain the over all oxidation products, 
several assays are required.  In our assay, detection and quantitation of multiple analytes 
is achieved by multiple-channel monitoring.  It quantifies six oxidized tyrosine species 
and the corresponding precursors simultaneously, which provides a snapshot of EPO or 
MPO induced oxidative stress in vivo. 
Second, unique isotope-labeled internal standards were used to insure the quality of 
data.  The preparation lost was calibrated by adding the isotopically labeled internal 
standard. [13C6] ring isotopically labeled oxidized tyrosine and universally labeled 
tyrosine, phenylalanine (i.e. all carbons 13C, all nitrogen 15N) as the internal standard 
prior to protein hydrolysis. Unique universally labeled oxidized tyrosine species serve 
internal quality control to monitor artifact generation. Multiple distinct natural abundance 
oxidized tyrosine species were identified and quantified by the corresponding [13C6] ring 
labeled isotopomer, while simultaneously the ions possessing the anticipated m/z 
transitions for universally labeled oxidized amino acids were monitored as an indicator of 
the generation of preparative oxidation products.   
Finally these mass spectrometry based approaches can be used to detect oxidized 
tyrosine species and their precursors, tyrosine and phenylalanine respectively, in different 
biological matrices including plasma, BAL, CSF and tissue.  High sensitivity and 
reproducibility ensures that our assay is a powerful tool to explore the free radical 
induced oxidation in vivo.  These unique properties suggest protein-bound oxidized 
residues can serve as molecular probes to identify the underlying oxidation pathways in 
diseases like atherosclerosis and cancer.  
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CHAPTER III  
PEROXIDASE PROMOTE PROTEIN BROMINATION IN 
MULTIPLE MOUSE ACUTE IMFLAMMATION MODELS 
 
3.1 Introduction 
Asthma is an increasing health problem in the developed countries.  In the United 
States, over 17 million individuals, many of them are children, suffer form this chronic 
pulmonary disease 1, 2.  The major symptoms of this airway obstruction include chronic 
airway inflammation, recurrent recruitment and activation of leukocytes including 
eosinophils and T cells into airway 3, 4.  Eosinophil is one of the terminal effectors of the 
innate immune system and specifically recruited to the inflammation sites.  Over decades, 
numerous studies support that eosinophil activation plays a vital role in airway 
obstruction and lung dysfunction.  Significantly increased eosinophils and their unique 
granule proteins, including eosinophil peroxidase (EPO) and eosinophil cationic protein 
(ECP), have been detected in peripheral blood, bronchoalveolar lavage (BAL), induced 
sputum and bronchial mucosa specimens recovered from asthma patients 5-7. 
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The activated eosinophil participates host defense by generating reactive oxygen species, 
including superoxide (O2•−) and hydrogen peroxide (H2O2), and simultaneously releasing 
its unique granule proteins in response to the antigen stimulation 8, 9.  EPO is account for 
nearly 25% of the total protein mass of the secondary granule 10.  Elevated EPO activity 
was also observed in specimen recovered from patients with acute severe asthma 11.  In 
addition, EPO activities was associated with prompting mast cell degranulation, 
activating platelets, and increasing the phagocytic capabilities of macrophages 12, 13.   
In vitro studies indicate that EPO utilizes hydrogen peroxide to oxidize numerous 
substrates including halide and pseudohalide thiocyanate 4, 14.  EPO selectively utilizes 
physiological level of Br− (20-150 μM) over Cl− (100 mM) to generate hypobromous acid 
(HOBr).  Further, HOBr and its conjugate base (OBr−) react with amine and further 
oxidize α- or β- amino acid.  However, both oxidation products are labile and easily 
decomposed to aldehyde 15, 16.  N- dibromoamine (RNBr2) and N-bromoamine species are 
easily reduced to non-informative products 17, 18.  Due to the evanescence character of 
these reactive brominating species (RBS), it is impossible to use the RBS as a probe to 
study the mechanism of EPO catalyzed oxidation in vivo.  Direct evidence of EPO 
induced protein modification in vivo has not been reported yet. 
As an alternative way, stable oxidation products may serve as molecular 
fingerprints to record peroxidase catalyzed oxidation in vivo.  Our previous study 
indicated that EPO utilized H2O2 and physiological concentrations of Br− (20-150 μM) to 
oxidize free or protein-bound L- tyrosine 19.  Two major products were detected by 
ultraviolet-visible (UV) detector with distinct retention time on the reverse phase HPLC.  
The two major products were further identified as 3-bromotyrosine (3-BrY) and 3,5-
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dibromotyrosine (3,5-diBrY) by electrospray ionization mass spectrometry and 
multinuclear (1H and 15N) NMR spectroscopy.  The stability of 3-BrY was demonstrated 
by over 95% recovery even after treated by  HCl (6N, 1% phenol) or methane sulfonic 
acid (MSA, 4N, 1%phenol) at 110 °C for 24 hours (data not shown).  The distinct 
structure and relative stability of 3-BrY suggest that 3-BrY may be used as a specific 
marker of peroxidase-catalyzed oxidation pathways in vivo.  Recent studies indicate that 
significantly elevated protein-bound 3-BrY is recovered in sputum in asthmatic patients 
compared to that in controls.  The levels of this bromination product highly positively 
correlates with eosinophil peroxidase protein mass (r = 0.79, p< 0.0001) 20.  We also 
found that protein-bound 3-BrY level increased 10-fold in bronchoalveolar lavage (BAL) 
fluid recovered from asthmatic patients but only 2, 3-fold increased in that from healthy 
controls after segmental allergen challenge21.  Both in vitro and in vivo studies suggest 
that 3-BrY can be used as a chemical probe to study eosinophil peroxidase catalyzed 
protein bromination in vivo.   
In current study, we monitored the generation of 3-BrY during allergen challenge 
to evaluate the relative contribution of EPO in promoting protein bromination in vivo.  
Multiple distinct inflammation models were used to generate robust eosinophil-rich 
infiltration into airways or peritoneum in EPO knockout (EPO-/-) and wild-type (EPO+/+) 
mice.  The unique universally labeled tyrosine (13C9, 15N1 Tyr) was added prior to protein 
hydrolysis to quantify natural abundance tyrosine and monitor the potential preparative 
bromination generation during sample processing.  Using this highly sensitive, self-
quality control assay, the in vivo protein bromination is evaluated.  Significantly elevated 
3-BrY generation was observed in EPO+/+ mice in both models after allergen challenge.  
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In addition, in helminth protein induced peritonitis model, significantly elevated 3-BrY 
formation was observed after M.Corti. challenge (7-fold increases).  Further, dramatic 3-
BrY generation (50-fold increases) was observed after zymosan triggered eosinophil 
activation and degranulation in EPO+/+ mice.  In contrast, no detectable 3-BrY was 
recovered in specimen from EPO-/- regardless the treatments.  These results support the 
EPO as the major pathway for generating protein-bound 3-BrY in vivo. 
3.2 Experimental Procedures 
Reagents 
Reagents including H3PO4, NaH2PO4, and Na2HPO4 were purchased from Fisher 
Chemical Co.  Chelex 100 resin (200-400 mesh, sodium form) was purchased from 
BioRad.  Methane sulfonic acid and bromide were from Fluka Chemical Co.  
(Ronkonkoma, NY).  L-[13C6] tyrosine, [13C915N1] tyrosine, and L-[2H4] tyrosine were 
purchased from Cambridge Isotopes, Inc.  (Andover, MA).  All other reagents were 
purchased from Sigma unless otherwise indicated.  All gases were of the highest quality 
available (Praxair, Cleveland, OH).  
Animals 
The animal studies described here were all performed using approved protocols 
from the Animal Research Committees of the Cleveland Clinic Foundation and Mayo 
Clinic Foundation.  129/SvJ age- and sex-matched EPO knockout (KO) and wild-type 
(WT) mice were used for the allergen lung challenge and helminth antigen-induced 
peritonitis studies. 
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Aeroallergen Lung Challenge Model 
EPO-KO and WT mice were sensitized by intraperitoneal injection with either 
normal saline as control or 20 µg of ovalbumin (OVA, grade IV, Sigma) and 2.25 mg of 
Imject® Alum (Pierce) on days 0 and 14.  On days 24, 25, and 26, animals were 
challenged with 20-min inhalations of a 1% OVA or normal saline aerosol.  On day 28, 
bronchoalveolar lavage (BAL) fluid was obtained by normal saline lavage. The recovered 
BAL was centrifuged at 1000 rpm at 4 °C for 10 mins to remove cells.  The supernatant 
was frozen and stored under nitrogen at approximately –80 °C until analysis.  Lung tissue 
specimens of wild-type (EPO+/+) and EPO-/- mice were harvested 48 hours following the 
last OVA aerosol challenge (i.e., the maxima of post challenge eosinophilia). Lung tissue 
was immediately rinsed with an ice-cold anti-oxidant cocktail buffer (50 mM phosphate 
buffer (pH=7.4), 100 µM diethylenetriaminepentaacetic acid (DTPA), 100 µM butylated 
hydroxytoluene (BHT)) and stored under argon at approximately –80 °C until analysis. 
Helminth Protein-induced Peritonitis Model 
EPO-KO and WT mice were sensitized by subcutaneous injection with 250 µg of 
whole protein extract from helminth Mesocestoides corti and 8 × 109 heat-killed pertussis 
organisms (Michigan Department of Public Health, Lansing, MI).  Animals were 
challenged with normal saline or 200 µg of M. corti. on day 21 by intraperitoneal 
injection.  Peritoneal cavity cells were harvested 72 hours later by lavage with 1x PBS 
containing 100 µM BHT and 100 µM DTPA, 5% FCS and 20 U/mL heparin.  For some 
animals, the elicited peritoneal leukocytes (typically >2 × 106 cells, ~ 25% eosinophils) 
were activated by intraperitoneal injection with zymosan (250 mg/kg of body weight).  
Peritoneal lavage was performed 4 h after zymosan injection.  Recovered leukocytes 
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were washed three times with centrifugation/resuspension in 1x PBS before used. 
Differential counts of cytospin preparations of these cells revealed that neutrophils 
composed < 1% of all sample examined.  The cell-free lavage fluid was overlaid with 
argon and immediately stored at ~ –80 °C until analysis.  Superoxide production was 
measured as the superoxide dismutase-inhibitable reduction of cytochrome C 22 using 
eosinophils isolated from EPO-KO and WT mice.   
Immunocytochemical Detection of Eosinophils  
Sections of lung tissue (4 µm) were assessed for the infiltration of eosinophils 
using a rat mAb (14.7.4) specific for murine MBP-1 23. Immunocytochemical staining 
was performed with DAB-peroxidase detection reagents (Vector Laboratories, 
Burlingame, CA) as described previously 24. 
Cytochemical Detection of EPO  
Cytospin preparations of peritoneal cavity cells harvested from MCA-
sensitized/challenged mice were prepared using a Cytospin3 (Shandon Scientific, 
Cheshire, U.K.).  The slides were subsequently fixed for 30 seconds at 4°C in a formalin-
acetone buffer (0.75 mM Na2HPO4, 7.5 mM KH2PO4 (pH 7.5), 45% (v/v) acetone, and 
10% (w/v) formaldehyde), washed in tap water for several minutes, and stained (10 min 
at room temperature) for EPO activity using a diaminobenzidine (DAB)-H2O2 phosphate 
buffer (6 mM Na2HPO4, 286 mM KH2PO4 (pH 7.4), 2 mM (3',3')-DAB 
tetrahydrochloride (Sigma, St. Louis, MO), 0.01% H2O2 (Sigma), and 8 mM NaCN 
(Aldrich, Milwaukee, WI)) as described earlier 25.  The concentration of CN- (8mM) was 
used to selectively inhibit the activity of myeloperoxidase that may be present in the 
sample.  The staining reactions were terminated by washing under tap water, and the 
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slides were counterstained with Harris hematoxylin (Sigma) before dehydration through 
an ascending series of ethanol washes, incubation in xylene, and mounting with Permount 
(Fisher Scientific, Pittsburgh, PA).  
Endpoint Colorimetric Assessment of EPO Activity  
The amount of EPO activity was determined by an endpoint colorimetric assay, as 
described previously 26.  To determine the amount of EPO activity within cells, peritoneal 
cavity cells and/or leukocytes recovered from BAL fluid were washed in Kreb’s buffer 
(118 mM NaCl, 25 mM NaHCO3, 11 mM glucose, 1 mM NaH2PO4•H2O, 5 mM KCl,  
0.5 mM MgCl2•6H2O, and 2.5 mM CaCl2•6H2O (pH 7.4)) and counted on a 
hemocytometer.  The number of eosinophils in a given leukocyte population was 
determined by differential cell counts of cytospin preparations.  Dilutions ranging from 
102 to 104 eosinophils were seeded in 50-µl volumes in a 96-well microtiter plate, and 
EPO activity was measured in each lysate through the addition 75 µl of  
o-phenylenediamine-H2O2 buffer (50 mM Tris-HCl (pH 8), 0.1% Triton X-100, 4 mM 
H2O2, and 10 mM of the EPO (vs myeloperoxidase)-specific substrate  
o-phenylenediamine).  The reactions were allowed to proceed at room temperature for 30 
minutes before adding 50 µl of stop buffer (2N H2SO4).  Absorbance of each sample was 
measured at 490 nm using a Vmax Kinetic Microplate Reader (Molecular Devices, 
Sunnyvale, CA).  EPO activity present in BAL fluid was assessed by incubating 
undiluted cell-free BAL fluid with o-phenylenediamine-H2O2 buffer at 37°C for 30 
minutes 27.  Colorimetric readings due to EPO activity were calculated as the difference 
in absorbance measurement of each reaction with a duplicate reaction conducted in the 
presence (30 mM) of the peroxidase inhibitor 3-amino-1,2,4-triazole.  The fraction of 
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EPO released from airway eosinophils was estimated by measuring the amount of EPO 
activity in cell-free BAL fluid as a function of total EPO activity in the BAL (i.e., the 
sum of EPO in the BAL fluid and EPO in airway eosinophils).  EPO activity was 
calculated from a standard curve established using 1 x 102–5 x 105 eosinophils purified as 
a homogeneous population (99% pure) from an IL-5-transgenic mouse line 28.  The 
reading at 490 nm of each sample (i.e., the BAL fluid and BAL cell pellet derived from 
each mouse) was used to obtain the equivalent amount of EPO contained in a known 
number of eosinophils as determined from this standing curve.  
Preparation of Isotope Labeled Internal Standard 
3-Bromo [13C6] tyrosine (13C6 3-BrY) was prepared by adding freshly made 
NaOBr (final conc. of 1.5 mM) into a constantly stirring solution containing L-[13C6] ring 
labeled tyrosine (final conc. 1 mM) and phosphate buffer (Final conc. 20 mM, pH= 7.4).  
The resulting solution was incubated at 37°C for 2 hours before the addition of 
trifluoroacetic acid (TFA) to terminate the reaction.  The acidified solution was 
concentrated and isolated by a reverse-phase high performance liquid chromatography 
(HPLC) 29.  Isotopically labeled tyrosine (13C6 Y) and 3-bromotyrosine (13C6 BrY) was 
eluted with a linear gradient generated with solvent B (0.1% TFA in methanol, pH=2.0) 
as follows: 0–5mins, 0% solvent B; 5–25mins, 0–100% solvent B; 25–28mins, 100 % 
solvent B, 28–33 mins, 100%–0% solvent B.  The isotopically labeled 3-BrY was then 
dried in speed vacuum and kept in –20°C freezer until use.  Ring labeled 3-
Bromotyrosine was reconstituted with chelex-treated water. The identity and purity of 
isotopically labeled 3-BrY was confirmed by LC/ESI/MS/MS.  
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Tissue Collection and Preparation 
On the day of analysis, tissues were thawed in sealed plastic vials under cool 
running water.  All tissue processing steps were performed at approximately 4°C.  
Samples were homogenized in PB buffer containing 100 µM BHT and 100 µM DTPA 
using a Potter-Elvehjem tissue homogenizer with a PTFE pestle.  Protein concentration of 
lung tissue homogenate or extracellular lavage was determined using a Bradford-based 
Bio-Rad protein assay with IgG as the protein standard.  Protein (500 µg) was delipidated 
and desalted using three sequential extractions with a single phase mixture of 
H2O/methanol/H2O-saturated diethyl ether (1:3:8 v/v/v).  For each extraction, single 
phase mixture was vortexed, stored at approximately –20 °C for 40 minutes.  The protein 
was precipitated by centrifuging at 4000 rpm for 20 mins at ~ 4°C.  After discard 
supernatant, protein pellet was dried under nitrogen steam.  For each sample, known 
amount 13C ring-label 3-Bromotyrosine (13C6 BrY, 1.0 pmol) and universally labeled 
tyrosine (13C9, 15N1 Y, 10 nmol), were added prior to protein hydrolysis.   
Protein Hydrolysis and Derivatization 
Preliminary studies demonstrated in acidic conditions, like methanesulfonic acid 
(MSA, 4N, 1% phenol) or hydrochloric acid (HCl, 6N, 1% phenol) solution, free tyrosine 
was stable at 110 °C for 24 hours.  Artificial halogenation was eliminated by substituting 
MSA (4N) for HCl (6N) and washing protein with single phase mixture prior to acidic 
hydrolysis.  Tubes were capped with gas-tight valves and alternately degassed and purged 
with argon for 3 times.  Protein pellet were hydrolyzed by 4N methanesulfonic acid 
supplemented with 1% phenol at 110 °C for 24 hrs under argon atmosphere.  The 
potential debris generated during protein hydrolysis was removed by passing a mini 
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solid-phase C18 column (Supelclean LC-C18 SPE mini-column, 3 ml; Supelco, Inc., 
Bellefone, PA).  Briefly, protein hydrolysates (0.5 mL) were diluted with 1.5 mL Chelex-
treated water and load on pre-conditioned SPE columns. Following sequential washes 
with 2 ml of water (0.1% TFA), 3-bromotyrosine and tyrosine were eluted with 2 ml of 
30% methanol (0.1% TFA).  The resulting amino acid solutions were then dried under 
vacuum.  
Before loading on a GC column, alkylation and acylation reactions were 
accomplished to improve the gas chromatographic properties and enhance the sensitivity 
of analytes.  n-Propyl esters of tyrosine or 3- bromotyrosine were generated by adding a 
mixture of 100 μl of n-propanol: concentrated HCl (3:1, v: v), and heating at 65°C for 75 
minutes (Eq 1.).  Reaction products were dried under vacuum and reconstituted with  
100 μL of pentafluoropropionic anhydride: ethyl acetate (1:3, v: v) solution and 
incubated at 65°C for 15 minutes to generate its n- propyl, per pentafluorylproprionyl 
derivatives (Eq 2).  After evaporation under vacuum, derivatized amino acids were 
reconstituted in 100 μL of ethyl acetate. An aliquot of resulting solution (1 μL) was 
loaded on GC/MS for 3-BrY analysis. 
HO
X
CH2 CH
NH2
COOH HO
X
CH2 CH
NH2
COOC3H7
C3H7OH/HCl
65 C, 75 mins
Eq 1.
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C6F10O3/C4H8O2
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X= H, Br 
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Gas Chromatography-Mass Spectrometry  
The amino acid derivatives were separated and analyzed on Trace GC-2000 gas 
chromatography with online Voyager Mass Spectrometer (ThermoFinigann, San Jose, 
CA).  The separations were achieved on a 15m long, low bleeding RTX-200 MS column 
(Restek, 0.25mm i.d., 0.25μm film thickness).  Helium was used as carrier gas at a 
constant flow rate of 1 mL/min.  The initial oven temperature was maintained at 40°C for 
1 minute, and then the temperature was increased to 150°C at 30°C/min, held at 150°C 
for 0.5 minute, and then increased to 280°C at 15°C/minute.  Tyrosine was analyzed by 
split mode (split ratio, 50:1) and 3-Bromotyrosine was analyzed by splitless mode 
respectively.  Consistent septum purge was set on to keep septum clean.  The injector, 
transfer line and source temperature were set at 250°C, 250°C and 200°C respectively.   
Derivatized tyrosine and 3-Bromotyrosine were detected and quantified by the 
Voyager mass spectrometer via negative-ion chemical ionization (NICI) with selected ion 
monitoring (SIM) mode.  The emission current, electron energy and detector voltage was 
set at 350 μA, 70Ev and 500 volts, respectively.  n- propyl- per pentafluoroproprionyl 
derivative of natural abundance 3-Bromotyrosine (12C9 BrY) was monitor at mass charge 
ratio (m/z) of 445 (for 79Br), 447 (for 81Br), and their corresponding isotopically labeled 
internal standard (13C6 BrY) at m/z ratio of 451 (for 79Br), 453(for 81Br).  To detect the 
artificial generation during the hydrolysis and derivatization step, universally labeled  
3-Bromotyrosine (13C9, 15N1BrY) was routinely monitored at m/z of 455 (for 79Br), 457 
(for 81Br).  n- propyl- per pentafluoroproprionyl derivative of tyrosine (12C9 Y) and the 
corresponding isotopically labeled internal standard (13C9 15 N1 Y) were monitored at m/z 
ratio of 367 and 377, respectively.  Both tyrosine and 3-bromotyrosine were base line 
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resolved under current GC condition with at least 9-10 scans per chromatographic peak.  
The 3-bromotyrosine content was normalized to the content of its precursor, tyrosine. 
Statistical Analyses  
Unless otherwise indicated, data were analyzed using an unpaired Student’s t tests.  
The threshold for significance was set at p ≤0.05.  The values for all measurements are 
expressed as the mean ± S.D.  
3.3 Results 
OVA Challenge Induce eosinophilia in Both Wild Type and Knockout Mice  
The localization of eosinophils within compartments of the lung after allergen 
challenge was initially determined by an anti-mouse MBP rat mAb that was previously 
demonstrated to be specific for eosinophils 24.  Figure 3.1 shows that although small 
numbers of eosinophils are homeostatic resident cells in the lungs of both EPO+/+ and 
EPO-/- mice, OVA challenge resulted in an influx of eosinophils into the 
peribronchial/perivascular regions of EPO+/+ and EPO-/- mice.  The localization and 
number of eosinophils (150–200 eosinophils per millimeter squared) in the lungs after 
OVA challenge were indistinguishable between EPO+/+ and EPO-/- mice.   
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 Figure 3. 1  OVA-Sensitized/Challenged Induced Eosinophilia in EPO-/- and 
EPO+/+ Mice 
Trafficking of eosinophils to the perivascular and peribronchial regions of Wild 
type (EPO+/+) and Knockout (EPO-/-) lungs was assessed by immunocytochemistry using 
a rat mAb (14.7.4) specificially for mouse MBP-1.  Saline control groups: A, EPO+/+ and 
B, EPO-/-.  OVA–challenged groups: C, EPO+/+; and D EPO-/-.  Arrows indicate 
eosinophils localized in the parenchyma of saline control EPO+/+ and EPO-/- mice.  No 
differences in the number or specific location of eosinophils recruited to the lung were 
observed between similarly treated mice of either genotype.  Scale bar = 100 µm.   
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Eosinophils from Knockout Mice Are Peroxidase Deficient  
The loss of EPO activity in knockout mice was demonstrated by cytochemical 
staining of peritoneal cavity exudate cells recovered following sensitization/challenge of 
mice with a whole-protein extract from the helminth M. corti.  Figure 3.2 A shows that 
eosinophils from EPO-/- mice were devoid of peroxidase activity (i.e., CN-–resistant 
peroxidase activity (DAB staining) was demonstrated only in eosinophils from EPO+/+ 
and EPO+/- mice).  The loss of eosinophil peroxidase activity in cells from EPO-/- mice 
was further demonstrated using an endpoint colorimetric assay detecting EPO in lysate of 
the peritoneal cavity exudates (Figure 3.2B).  The peroxidase activity of EPO+/- 
eosinophils was roughly 50% of that found in EPO+/+ eosinophils, suggesting that EPO 
levels in eosinophils are proportional to the number of wild-type EPO alleles present.  
Eosinophils recovered from homozygous knockout mice derived from ES cell clone 6 or 
57 were shown to be EPO activity deficient using both the peroxidase cytochemical 
detection and the endpoint colorimetric assay.  Thus, mice derived from either ES clone 
were considered equivalent.  Subsequent studies were performed on animals derived from 
clone 57.  
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 Figure 3. 2  EPO Activity Is Absent in the Eosinophils of Knockout Mice.   
A, EPO activity is detected only in eosinophils recovered from EPO+/+ and EPO+/- 
mice in response to allergen challenge.  B, EPO activity presented in eosinophils is in 
proportion to the number of wild-type alleles.  Assessments of peroxidase activity (490 
nm), the number of eosinophils is plotted as a function of peroxidase activity in the 
peritoneal cavity exudate. Eosinophils activity of EPO+/- contain half the peroxidase 
activity as EPO+/+ cells.  No peroxidase activity was detectable in cell lysate from EPO-/- 
mice regardless of the input number of eosinophils.  The points comprising each curve 
represent the means of assays performed on exudated cells derived from four different 
animals within each group.  Error bars at each point represent ± SEM. 
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GC/MS Analysis of 3-Bromotrysine  
Negative-ion chemical ionization (NICI) mass spectrum of 1-propyl-per 
pentafluoroproprionyl derivative of 3-Bromotyroisne was illustrated in figure 3.3.  
Compared with low intensity of molecular ions (M•¯, 593 for 79Br and 595 for 81Br), the 
base ion was observed at m/z 261 ([M− -CH2C5H4BrOOC2F5]), which was lack of 
structure information.  Other major fragment ions were observed with isotopic character 
at m/z 573 ([M− -HF] for 79Br), m/z 575 ([M− -HF] for 81Br), m/z 445 ([M− -CF3CF2COH] 
for 79Br) and m/z 447 ([M− -CF3CF2COH] for 81Br).  The isotopic distribution of natural 
abundance 3-BrY was confirmed by bromine-containing product ions (similar abundance 
between 79Br: 81Br, 573: 575 and 445: 447).  Product ions with corresponding isotopic 
information 445, 447 were used to quantify natural abundance 3-Bromotyrosine because 
their preserved the structure information and provided a better sensitivity compared to the 
molecular ions (m/z 573 and 575).   
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Figure 3. 3  Negative-ion chemical ionization mass spectrum of 3-bromotyrosine   
1-propyl-per pentafluoroproprionyl derivative of 3-Bromotyroisne was 
derivatized and analyzed by GC/MS in the NICI mode as described in experimental 
procedures.  The structure of derivatized 3-BrY and its proposed fragmentation is 
illustrated above.  Molecular ions were observed at m/z ratio of 593 (for 79Br) and 595 
(for 81Br). 
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Elevated 3-BrY Generation in EPO+/+ Mice after Allergen Challenge  
The levels of protein-bound 3-BrY recovered from lung homogenate and 
bronchoalveolar lavage (BAL) in an aeroallergen lung challenge model from wild-type 
(WT, EPO+/+) and knockout (KO, EPO-/-) mice were quantified by isotope dilution 
GC/MS assay to evaluate the potential involvement of EPO in the generation of  
3-Bromotyrosine in vivo.  The topical chromatograms of 3-BrY in tissue specimen 
recovered from an OVA–treat EPO+/+ mouse are presented in Figure 3.4.  For 
quantitation purpose, each chromatographic peak contained a minimum 9-10 scans.  The 
natural abundance 3-BrY was identify by the corresponding isotope labeled internal 
standard (13C6 BrY) and confirmed by the equal isotope abundance of bromine (79Br:81Br, 
approximately 50:50).  Native tyrosine and universally labeled tyrosine (13C9 15 N1 Y) are 
identical in chemical structure expect that universally labeled tyrosine (13C9 15 N1 Y) has 
ten extra atomic mass unit (10 Da). Therefore identical chemical character and same 
chromatographic behavior should be observed in sample preparation and GC separation.  
If trace amount of bromide was left in the system and caused bromination during sample 
preparation, universally labeled 3-bromotyrosine (13C9 15 N1 BrY) will be generated 
proportionally.  As demonstrated in Figure 3.4, there was no detectable universally 
labeled 3-bromotyrosine (13C9 15 N1 BrY) indicating no detectable artifact generation 
during sample process. 
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Figure 3. 4  Detection of 3-bromotyrosine in Mouse Lung Tissue by GC/MS   
Mouse lung tissue specimen from OVA–treated EPO+/+ mouse was prepared and 
analyzed by GC/MS as described in experimental procedures.  Native 3-BrY (m/z, 445 
and 447) was identified by having the appropriate retention time compared to the 
corresponding internal standards 13C6 BrY (m/z, 451 and 453).  No detectable ex vivo 
bromination generation (13C9, 15N1 BrY, m/z, 455 and 457) was observed.   
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The loss of peroxidase activity in knockout animals during allergen challenge was 
functionally demonstrated by assessing an EPO-specific oxidation product, 3-BrY, in 
whole-lung homogenates from EPO+/+ and EPO-/- mice using multiple allergen challenge 
models.  EPO+/+ (WT) and EPO-/- (KO) mice were pre-sensitized to antigen (Ovalbumin, 
OVA) and then exposed to nebulized antigen.  An eosinophil-rich leukocyte infiltration 
was observed in lung and airway in both genotypes (Figure 3.1.).  This similarity of 
eosinophil infiltration was further confirmed by demonstrating comparable eosinophilia 
recovered from bronchoalveolar lavage in WT and EPO-KO mice after OVA challenge 
(BAL eosinophils, EPO+/+-, 0.97±0.29, EPO-/-, 1.0 ±0.30, p> 0.6).  Lung specimens and 
BAL lavage of EPO+/+ and EPO-/- mice were harvested 48 hr following the last OVA 
aerosol challenge.  The specimens were prepared following protein precipitation, acid 
hydrolysis, solid phase extraction and derivatization.  The level of 3-BrY in tissue or 
BAL specimens from OVA–treated EPO+/+ and EPO-/- mice was normalized to the 
content of its precursor, tyrosine, and presented in Figure 3.5.  In EPO+/+ mice, the 
contents of 3-BrY were significantly increased in whole-lung homogenates and BAL 
after OVA challenge compared to saline-challenged controls (3-BrY/Y (µmol/mol), lung 
tissue, OVA, 215, NS, 0, p< 0.05; BAL, OVA, 96, NS, 0, p< 0.05).  No detectable 3-BrY 
was observed in EPO-/- mice regardless treatments.  The mouse Ovalbumin challenge 
model did elicit a robust eosinophil-rich leukocyte infiltration into the lung and airway 
(Figure. 3.1.).  However, assessments of free EPO activity from BAL fluids from OVA–
treated WT mice only account about 9% of total activity.  This limited degranulation may 
contribute that only nominal protein bromination (3-BrY/Y, 96 µmol/mol) was observed 
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in WT mice lavage after OVA challenge compared to that recovered in mild asthmatics 
after segmental allergen challenge (3-BrY/Y, 1085 µmol/mol) 21, 31. 
To further investigate EPO catalyzed protein bromination in vivo, an alternative 
inflammation model, M. Corti/Zymosan peritonitis model, were applied and protein-
bound 3-BrY was monitored.  EPO+/+ and EPO-/- mice were sensitized to induce 
peritonitis and peritoneal lavage was harvested 72 hr after challenge.  Pilot study 
indicated that sensitization/challenge helminth protein from M. Corti elicited a more 
robust eosinophil-rich leukocyte infiltration into the peritoneum 72hr after the challenge 
(topically > 2x106 cells, 25-30% eosinophils).  In addition, yeast cell wall zymosan was 
injected into the peritoneum to trigger extensive leukocyte activation and degranulation.  
For some animals, as indicated, peritoneal lavage was recovered 72 hours after M. Corti 
challenge and/or 4 hours after subsequent to intraperitoneal injection of zymosan (4hr).  
Stable isotope dilution GC/NICI/MS quantification of protein-bound 3-BrY was 
performed (Figure 3.6).  Basal level 3-BrY levels were only observed in EPO+/+ mice 
(BrY/Y, 10 ± 23 µmol/mol). 3-BrY levels were significantly increased in EPO+/+ mice 
following M. Corti challenge compared with normal saline (7-fold increase, M. Corti, 71 
± 58 µmol/mol; normal saline, 10 ± 23 µmol/mol, p <0.001). After M. Corti and zymosan 
treatment, there was 50-fold increases over basal level 3-BrY generation (M. 
Corti/zymosan, 499 ± 390µmol/mol; normal saline, 10 ± 23 µmol/mol, p <0.001). These 
results confirm that elevated protein bromination consistent with helminth protein 
induced peritoneal eosinophilia.  Zymosan induced leukocytes activation and 
degranulation results in extensive EPO-catalyzed protein bromination in EPO+/+ mice.  
However, 3- BrY was undetectable in the peritoneal lavage recovered from EPO-/- mice 
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regardless the treatments.  Parasite antigen induced extensive eosinophilia and zymosan 
treatment stimulated eosinophil activation and degranulation failed to generate detectable 
3-BrY in EPO -/- mice.  This evidence strongly supports that loss of EPO activity links the 
absence of protein bromination in vivo.  Significantly elevated protein bromination in 
EPO+/+ mice after allergen challenge supports the hypothesis that activated eosinophils 
associate with protein bromination in vivo.  3-BrY serves as a specific molecular 
fingerprint for EPO catalyzed bromination in vivo.   
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 Figure 3. 5  Elevated 3-BrY Generation in EPO+/+ Mice after Allergen Challenge   
The lung/BAL specimens of EPO+/+ and EPO-/- mice were harvested 48 hr after 
ovalbumin (OVA) or normal saline (NS) aerosol challenge.  Isotope dilution GC/MS 
analysis of 3-BrY/Y content: (A) in lung homogenates and (B) in extracelluar lavage 
protein.  The 3-BrY level was normalized to its precursor, tyrosine. Numbers in the 
parentheses represent the sample size of each group.  Data represent the mean ± SD.   
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Figure 3. 6  Detection of 3-BrY in Lavage in Helminth-induced Peritonitis Model   
EPO+/+ and EPO-/- mice were sensitized by subcutaneous injection with whole 
protein extract from the helminth M. corti.  Animals were challenged on day 21 by 
intraperitoneal injection with either normal saline (NS) or M. corti to elicit an eosinophil-
rich peritoneal infiltrate.  Where indicated, for some animals, peritoneal lavage was 
recovered 72 hours after M. Corti challenge or 4 hours after subsequent to intraperitoneal 
injection of zymosan.  The content of bromotyrosine in lavage supernatant was 
subsequently measured by GC/MS.  The level of 3-BrY was normalized to the protein 
content of tyrosine, the precursor amino acid.  Numbers in the parentheses represent the 
sample size of each group. Values represent mean ± S.D.  
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3.4 Discussion 
Peroxidase catalyzed protein modification may be implicated in respiratory 
disorders including asthma, rhinosinusitis 3, 4, 14, 32.  In vitro studies support reactive 
intermediates generated by MPO/EPO react with variety of targets including protein, 
lipid and genetic materials.  Detection and quantitation protein-bound of stable oxidation 
product has been used as a powerful tool to investigate peroxidase-catalyzed oxidative 
pathways both in vitro and in vivo 14, 33-36.  In present studies, we showed significantly 
elevated protein bromination in specimens recovered from EPO+/+ mice after allergen 
challenge in multiple distinct inflammation models.  Both OVA and M. Corti challenges 
elicited a remarkable eosinophil-rich leukocytes infiltration into inflammation sites.  Only 
nominal levels of 3-BrY were observed in lung tissue specimens recovered from EPO+/+ 
mice.  Zymosan, a potent trigger of leukocyte activation and degranulation, injected after 
M. Corti challenges resulted a dramatic elevation in protein bromination in vivo. No 
detectable protein-bound 3-BrY was observed in specimens recovered from EPO-/- mice 
regardless the allergen challenge treatments.  Our results support the EPO as the major 
pathway for generating protein-bound 3-bromotyrosine in vivo. 
 To examine the potential role of EPO in 3-bromotyrosine generation in vivo, it 
was fundamentally important to ascertain the genetic background of KO (EPO-/-) and the 
loss of EPO activity.  EPO knockout mouse was generated from 129/SvJ background by 
replacing 3 target exons 37.  Southern blot and RT-PCR were used to confirm the genetic 
background of in EPO-/- mouse37.  Electron Microscopy of eosinophils  from EPO-/- mice 
revealed the ultra structural changes of eosinophil secondary granules (detail in Ref 37).  
Cytochemical staining of eosinophils, which were recovered EPO-/- mice, demonstrated 
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the loss of EPO activity (Figure. 3.2A).  The loss of peroxidase activity in cells from 
EPO-/- mice was further evaluated by using an endpoint colorimetric assay. No detectable 
EPO activity in cell lysate from EPO-/- mice peritoneal cavity exudates (Figure. 3.2B). 
 The loss of EPO had no significant impact on the recruitment of leukocytes in 
EPO-/- mice after allergen challenge.  48 hours after aerosol challenge, the similar 
eosinophil infiltrations were observed in the lungs and airways recovered from EPO+/+ 
and EPO-/- mice.  The localization and number of eosinophils (150–200 eosinophils per 
millimeter squared) in the lungs after OVA challenge were indistinguishable between 
EPO+/+ and EPO-/- mice (Figure. 3.1).  This similarity was also confirmed by comparable 
total cell counts in bronchoalveolar lavage recovered from EPO+/+ and EPO-/- mice 
(eosinophils, EPO+/+ vs. EPO-/-, 0.97x104 vs. 1.0x104).  Using helminth protein-induced 
peritonitis model, a dramatic eosinophil-rich infiltration of leukocytes in peritoneum was 
observed 72 hours after re-challenge regardless genotype.  Comparable total cell count 
(>2x 106 cells) and differentials (~25-30% eosinophils) were recovered in the peritoneal 
lavage from EPO+/+ and EPO-/- mice.  
 The loss of EPO was associated with significantly elevated superoxide generation 
in OVA challenge model.  In vitro studies demonstrate that EPO-catalyzed free tyrosine 
or protein-bound tyrosine bromination can be inhibited by eliminated the presence of 
H2O2 or O2•- in the system 38.  To access EPO-catalyzed oxidation in vivo, the O2•- 
generation of eosinophils recovered from EPO+/+ vs. EPO-/- mice was compared.  
Superoxide production was consistently enhanced ~1.6 fold in eosinophils isolated from 
EPO-/- mice compared to EPO+/+ mice of homogeneous genetic background (26 ± 4.8 vs. 
41.5 ± 7.3 nmol/106 cells over one hr for WT vs. EPO-KO; p < 0.001).   
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In the current study, the sample preparation procedures were optimized to prevent 
artificial 3-BrY generation during sample preparation.  In vitro studies indicate trace 
amount of oxidized tyrosine can be generated at acidic condition in the present of 
corresponding substrates 39, 40.  Preliminary studies found that trace amount of 3-BrY was 
detected by LC/MS after tyrosine incubated with HCl (6N, ACS certified) at elevated 
temperature (data not shown).  To prevent ex vivo 3-BrY generation, tissue specimens 
were subjected to three sequential extractions with a single phase mixture of 
H2O/methanol/H2O-saturated diethyl ether (1:3:8 v/v/v) to remove trace amount of 
bromide.  Traditional protein hydrolysis protocol is carried out in 6 N HCl for 24 hrs at 
110 °C.  Our preliminary studies found HCl (6N, ACS certified) might bring trace 
amount of bromide into the system.  To eliminate the artificial bromination generation 
during protein hydrolysis, HCl (6N, 1% phenol) was substituted by methanesulfonic acid 
(MSA, 4N, 1% phenol).  The protein hydrolysis efficiency was examined by comparing 
500 μg bovine serum albumin (BSA) in HCl (6N, 1% phenol) with that in MSA (4N, 1% 
phenol) for 24 hrs at 110 °C (Table 3.1).  The resulting free amino acids solution (10 μL) 
was loaded on a C-18 ultrasphere column (Beckman, 5μm resin, 4.6mmx250mm) and 
detected by UV detector at 280 nm (HPLC gradient listed in experimental procedures).  
Similar hydrolysis efficiency was achieved by using MSA (4N, 1% phenol) for 24 hrs at 
110 °C (Table 3.1).  Constant boiling HCl (6N, ultra pure grade, 1 mL ampoule) was 
used in derivatization to eliminate potential contamination.   
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Table 3. 1  Protein Hydrolysis Efficiency 
 MSA (4N, 1% Phenol) HCl (6N, 1% Phenol) 
23565 25123 
24766 23294 
25194 20148 
Area 
23443 20892 
Mean 24242 22364 
Std 871 2277 
t test 0.201  
 
500 μg bovine serum albumin (BSA) was incubated with hydrochloric acid (6N, 1% 
phenol) or methanesulfonic acid (MSA, 4N, 1% phenol) for 24 hrs at 110 °C.  The 
resulting free amino acids solution (10 μL) was loaded on a C-18 ultrasphere column and 
detected by UV detector at 280 nm.   
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It is necessary to monitor the ex vivo protein bromination due to the complexity of 
biological matrices.  Mass spectrometry is superior to other techniques because of its 
better sensitivity and specificity.  Immunohistochemical approaches have been widely 
used to detect and localize post translational modification of protein within the tissue 
both in vitro and in vivo 41-43.  Immunochemical assay does not require extensive sample 
preparation 43.  However, cross-reaction and semi-quantitative character dramatically 
limit the utilization of this technique for quantitation purposes.  The creditability of the 
data is questionable due to lack of direct structural information of the analyte(s) 44, 45.  
High performance liquid chromatography (HPLC) and gas chromatography (GC) based 
approaches are developed to detect oxidized tyrosine species using ultraviolet-visible 
(UV), fluorescence, electrochemical detection (ECD) and mass spectrometer (MS) 
detector 46 40, 47, 48.  Both UV and ECD detector are limited by providing adequate 
sensitivity 49.  In addition, neither of them is able to identify any ex vivo oxidation 
generation 50.  Mass spectrometer and unique isotope labeled internal standard addition 
provided a powerful tool to detect the potential artifacts generation during sample 
processing.  Universally labeled tyrosine is added prior to protein hydrolysis to serve as a 
chemical detector of preparative oxidation.  Universally labeled tyrosine is structurally 
identical to the natural abundance tyrosine except the difference in molecular weight.  
During the sample preparation, if trace amount of anion ions are left in the acidic system, 
natural abundance tyrosine (12C9, 14N1 Tyr) and universally labeled tyrosine (13C9, 15N1 
Tyr) will be oxidized at the same reaction rate to generate distinct oxidation products 
which can be only distinguished by the mass spectrometer 39, 51.  In deed, universally 
labeled tyrosine (13C9, 15N1 Tyr) is served as an internal quality controller for the 
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potential ex vivo oxidized tyrosine generation to insure the final result only represent 
oxidation stress in vivo.  
 Finally, using stable isotope dilution GC/MS and multiple inflammation models 
in EPO+/+ and EPO-/- mice, we explore the mechanism of EPO-catalyzed bromination 
pathway in response allergen challenge in vivo.  Aerosolized saline challenge alone had 
no effect on the homeostatic level of eosinophils in the airways from EPO-/- and EPO+/+ 
mice.  After OVA challenge, significantly elevated eosinophils were recruited in both 
EPO-/- and EPO+/+ mice. Eosinophil recruitments were indistinguishable in either 
genotype. The loss of EPO in EPO-/- mice had no significant effect on eosinophil 
recruitment in response to allergen challenge compared to EPO+/+ mice.  Superoxide, one 
of the reactive oxygen species (ROS), may serve as the fuel for the leukocyte implicated 
oxidation.  Even though the enhanced superoxide generation of eosinophils was found in 
EPO-/- mice, protein bromination product was absent after OVA challenge.  One 
explanation for the enhance superoxide generation by eosinophil from EPO-/- mice might 
associate with the loss of EPO activity, which significantly decreased reactive oxygen 
consumption by EPO-dependent oxidation in vivo.   In helminth protein induced 
peritonitis model, the more eosinophil infiltration the higher bromination product was 
observed in EPO+/+ mice (M. Corti, 71±58 µmol/mol vs. Normal saline, 3-BrY/Y 10±23 
µmol/mol, p<0.01).  In addition, zymosan stimulation triggered eosinophil activation and 
degranulation results a 50-fold increase in 3-BrY content compared to the baseline 
challenged by normal saline (M. Corti + zymosan , 499±39 µmol/mol vs. Normal saline, 
3-BrY/Y 10±23 µmol/mol, p<0.001).  On the other hand, no detectable 3-BrY was 
observed in EPO-/- mice regardless treatments.  This strongly supports that protein-bound 
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3-Bromotyrosine serves a “molecular fingerprint” of EPO activation and induced 
modification in vivo.  Collectively, these results suggest that EPO is the major pathway 
for the generating protein-bound 3-BrY in these allergen challenge models in EPO+/+ and 
EPO-/- mice.   
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CHAPTER IV  
HIGH THROUGHPUT LC-MS/MS ASSAY FOR QUANTITATION 
OF PROTEIN OXIDATION BY DISTINCT PATHWAYS IN 
BIOLOGICAL MATRICES 
 
4.1 Introduction 
The failure of potential antioxidant strategies to influence the propensity to 
develop a number of disease processes has raised considerable debate over the 
significance of oxidative stress in disease pathogenesis. For example, α-tocopherol 
supplementation in human clinical trials of cancer chemoprevention1-3 and cardiovascular 
disease4-6 has for the most part failed to demonstrate clinical benefit. However, in 
virtually all large-scale human clinical "anti-oxidant" studies there was no convincing 
evidence that the interventions employed had any impact on oxidative events.  This is 
because concomitant systemic markers of oxidative stress were never performed, due in 
large part to limitations in current methodology that permits performance of such 
measures in a practical fashion on large numbers of clinical specimens.    
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Of interest, where molecular markers of oxidant stress have been performed on 
subjects supplemented with large doses of α-tocopherol, reductions in levels have not 
always been observed7, whereas drugs with proven clinical benefit, such as statins for 
cardiovascular risks, have shown potent systemic anti-oxidant effects as reflected by 
multiple distinct oxidant stress markers8, 9. 
 Numerous lines of evidence support a mechanistic role for oxidative processes in 
disease pathogenesis10-13. Increasingly, it is recognized that oxidative modification of a 
number of proteins participates in the pathogenesis of aging and a number of disease 
states including atherosclerosis, asthma and neurodegenerative disorders14-18. Protein 
modification by reactive nitrogen species and halogenating oxidants (both brominating 
and chlorinating species) lead to the generation of a number of stable products that can be 
identified in a wide range of biological samples8, 19-27. As a result, the pathways that 
promote protein modification have become potential targets for therapeutic intervention. 
In addition, the detection of these products, which can act as molecular fingerprints of 
disease processes (Figure 4.1), can potentially stratify patients according to their disease 
risk, as well as potentially indicate which patients are most likely to benefit from 
potential antioxidant promoting interventions8, 9, 23, 28.  
The leukocyte derived enzymes, eosinophil peroxidase (EPO) and 
myeloperoxidase (MPO), have proven roles in the promotion of oxidative modification of 
proteins in vivo. EPO, a granule protein secreted by activated eosinophils, preferentially 
utilizes hydrogen peroxide and bromide as co-substrates to form reactive brominating 
species including hypobromous acid (HOBr)29. MPO, secreted by activated neutrophils, 
monocytes and certain tissue macrophages, can catalyze the formation of reactive 
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chlorinating species such as hypochlorous acid (HOCl) and molecular chlorine (Cl2) by 
utilizing hydrogen peroxide and chloride30. Nitric oxide (NO)-derived oxidants may also 
be generated by EPO and MPO catalyzed pathways31-34, in addition to interactions with 
peroxynitrite (ONOO¯), a potent oxidant formed by the reaction of nitric oxide and 
superoxide35. Aromatic amino acid residues serve as prime targets for oxidative 
modification.  The side chain of tyrosine is preferentially modified by these reactive 
species to form a number of oxidative products that are chemically stable and can be 
detected in a wide variety of biological samples (Figure 4.1).  
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 Figure 4. 1  Chemical Structures of Molecular Fingerprints of Protein Oxidation 
In Vivo 
Hydroxyl radical can be generated by a redox-active metal ion (M2+) or a protein-
bound redox-active metal ion [Pr (M2+)] and reacts with phenylalanine to form meta-
tyrosine (m-Tyr) and ortho-tyrosine (o-Tyr). EPO and MPO generate reactive 
brominating species (RBS) and reactive chlorinating species (RCS) which oxidize 
tyrosine to form 3-bromotyrosine (BrTyr) and 3-chlorotyrosine (ClTyr).  Tyrosyl radical 
(·Tyr) cross reacts with tyrosine to form di-tyrosine (diTyr).  Nitrogen dioxide (·NO2) can 
be generated by enzymatic pathways working with peroxynitrite (ONOO¯) to oxidize 
tyrosine and form 3-nitrotyrosine. 
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Increasing evidence has emerged to highlight the role that oxidative protein 
modification plays in the promotion of a number of diseases18, 36, 37. Reactive nitrogen 
species have been implicated in the initiation of lipid peroxidation, protein nitration and 
subsequent conversion of low density lipoprotein (LDL) into an atherogenic form38-41. It 
has been demonstrated that systemic levels of protein-bound nitrotyrosine predicts a risk 
of atherosclerotic disease in clinical studies and that levels decline following 
administration of statin therapy, independent of the degree of LDL lowering8, 9. Further, 
breast cancer samples with a high microvascular density are associated with elevated 
tissue levels of nitrotyrosine42. Similarly, the content of apolipoprotein A-I chlorotyrosine 
in subjects is strongly associated with cardiovascular risk23. Moreover, levels of 
bromotyrosine in bronchoalveolar lavage (BAL) samples increase significantly following 
allergen challenge in asthmatic subjects22. Bromotyrosine levels are significantly elevated 
in BAL recovered from subjects with severe asthma21, and are elevated in both induced 
sputum24 and urine43 of asthmatic subjects. It has also been reported that meta-tyrosine 
and ortho-tyrosine, markers of protein oxidation by hydroxyl radical-like oxidants, can be 
detected in vivo in a range of inflammatory settings9, 44, 45.  
Because of the potential utility of protein oxidative modifications in determining 
mechanisms of disease pathogenesis and oxidative processes in vivo, a number of 
methods have been reported to quantify the levels of oxidized protein products in various 
biological samples. The presence of oxidized protein products in tissue samples and 
identification of their cellular origin have been demonstrated through several 
immunochemical techniques using antibodies that are specific for protein oxidative 
modifications 46-49. However, many molecular markers of protein oxidation that are of 
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interest do not yet have commercially available specific antibodies for their detection. 
Moreover, antibody-based methods in general may be limited in their ability to accurately 
quantify levels of individual specific oxidative products in varying sequence and protein 
conformational contexts50. This is because antibodies typically display some degree of 
cross-reactivity with other antigens and differing affinities for small haptens depending 
upon the structural/sequence context in where the antigen resides. Finally, until multiple 
specific antibodies and quantitative methods are developed, no current immunochemical 
assays can simultaneously quantify multiple structurally distinct oxidized amino acids 
and their precursors.  
Alternative analytical approaches for oxidized amino acid quantification typically 
involve in chromatographic separation of the components of protein hydrosylates by high 
performance liquid chromatography (HPLC) or gas chromatography (GC), followed by 
detection and quantification of oxidized aromatic amino acid species and their precursors 
(tyrosine and phenylalanine) by ultraviolet detector (UV), electrochemical detection 
detector (ECD), electron capture-negative chemical ionization mass spectrometry (EC-
NCI/MS) and electrospray ionization mass spectrometry (ESI/MS)25, 36, 51-56. Mass 
spectrometry is currently the only method that provides direct structural information of 
the analyte as well as permits simultaneous monitoring for intra-preparative generation of 
oxidative products during sample handling. The high sensitivity of mass spectrometry 
allows for the detection of trace amounts of analytes in biological samples10, 25, 32, 57, 58. 
Early mass spectrometry studies of oxidized amino acids employing isotopically labeled 
precursor amino acids for the first time revealed the generation of artifactual intra-
preparative oxidized amino acids such as 3-bromotyrosine (BrTyr), 3,5-
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dibrbromotyrosine (Br2Tyr)22, 59, 3-chlorotyrosine (ClTyr)22, 59, 3-nitrotyrosine 
(NO2Tyr)59-61, and o,o'-dityrosine (diTyr)59. Use of isotopically labeled precursors has 
subsequently been adopted by many others because of the power of the technique in fine-
tuning sample preparation methods that exclude intra-preparative oxidation25, 32.  
With accumulating evidence supporting a pivotal role for protein oxidation in a 
wide range of disease processes, substantial interest has focused on the development of 
analytical methods that can measure molecular markers of protein oxidation in vivo. 
However, the labor- and time-intensive proposition of analyzing clinical specimens for 
the presence of individual oxidation products in large scale human clinical studies 
presents a daunting challenge. The development of a mass spectrometry-based approach 
that permits simultaneous monitoring of an array of molecular markers of protein 
oxidation while monitoring for the presence of artifactual intra-preparative oxidation 
would appear to be a major advance in this field. Here we describe a highly sensitive and 
specific assay for simultaneous quantification of 3-chlorotyrosine, 3,5-dichlorotyrosine, 
3-bromotyrosine, 3,5-dibromotyrosine, o-tyrosine, m-tyrosine, o,o'-dityrosine, 
nitrotyrosine, and their respective precursor amino acids in biological tissues and fluids. 
The method involves use of high performance liquid chromatography (HPLC) with on-
line electrospray ionization tandem mass spectrometry (LC-ESI/MS/MS). The 
incorporation of synthetic 13C6-labled synthetic internal standards permits accurate 
quantification of each natural abundance analyte. Inclusion of 13C9, 15N-labeled precursor 
amino acids, tyrosine and phenylalanine, permits quantification of precursors and 
monitoring for artifactual generation of oxidative products during sample processing 
simultaneously. Use of column switching technique further enhances sample analysis 
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throughput, resulting in a robust overall method with practical utility for both larger scale 
clinical and animal model studies. The high sensitivity, specificity and detection of 
multiple oxidized tyrosine species of this analytical method provides a unique 
opportunity to both further delineate oxidative mechanisms in disease processes. It also 
will enable exploration of the potential clinical utility of specific protein oxidative 
modifications as diagnostic and prognostic indicators in human health and disease.  
4.2 Experimental Procedures 
Hydrochloric acid (optima), H3PO4, NaH2PO4, Na2HPO4 and all organic solvents 
were from Fisher Chemical Co. (Pittsburgh, PA). Methanesulfonic acid and liquid 
bromine were from Acros organics (New Jersey). Chelex 100 resin (200-400 mesh, 
sodium from) was from BioRad (Hercules, CA). L-[13C6] tyrosine, L-[13C6] 
phenylalanine and L-[13C9, 15N1] universally labeled tyrosine and phenylalanine were 
from Cambridge Isotopes (Andover, MA). All other reagents were purchased from Sigma 
(St. Louis, MO) unless otherwise indicated. All gasses were of highest quality available 
and were from Praxair (Cleveland, OH).  
Human Studies 
Normal levels of protein oxidation products in plasma were evaluated in samples 
obtained from sequential healthy subjects who responded to local advertisements or were 
participating in health care screenings following informed consent. Subjects who were at 
least 25 years old with no history or clinical evidence of coronary artery disease were 
eligible to enroll into study. These subjects had a mean (±SD) age of 52.0 (±11.9) years, 
25.7% were current smokers, 27.1% had a history of hypertension and 10% had a history 
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of diabetes. All participants provided written informed consents. The study protocol was 
approved by the Institutional Review Board of the Cleveland Clinic Foundation.  
Whole blood was collected into purple (EDTA) top vacutainer tubes and samples 
were spun at 4 °C for 10 min at 2500 rpm. Plasma was removed and spiked with a 100X 
stock solution of anti-oxidant cocktail comprised of diethylenetriaminepentaacetic acid 
(DTPA) and butylated hydroxytoluene (BHT), resulting in a plasma final concentration 
of 100 μM each. Specimens were snap frozen under Argon atmosphere in liquid nitrogen 
and stored at approximately –80 °C until analyses. 
Aeroallergen Lung Challenge Model 
The animal studies were performed using approved protocols from the Animal 
Research Committees of the Cleveland Clinic Foundation and University of Minnesota. 
Three groups of adult age- and sex- matched Hartley guinea pigs were sensitized by 
intraperitoneal injections of 500 μg of ovalbumin (OVA, grade IV, Sigma) with 50 mg 
aluminum hydroxide adjuvant on days 0 and 14. One group of animals (Group 1, n= 5) 
consumed a normal chow diet with drinking water throughout the study. On day 21 these 
animals were challenged with aerosolized normal saline to serve as controls. Group 2 
(n=6) received a normal chow diet with drinking water, while Group 3 (n= 6) received 
drinking water supplemented with 0.2% sodium thiocyanate (NaSCN). On day 21, 
animals in Groups 2 and 3 were both challenged by aerosolized normal saline 
supplemented with 0.1% OVA solution. The challenge was performed for one minute on 
five successive occasions, each separated by a minute of recovery. Two days later, the 
animals were sacrificed. Lung tissue was harvested, immediately rinsed in ice-cold 
normal saline and placed in 20 mM phosphate buffer saline (pH 7.4), supplemented with 
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100 μM BHT and 100 μM DTPA, and overlaid with argon prior to storage at 
approximately –80 °C until analyzed. 
Tissue Homogenization  
Samples were processed on the day of analysis. Tissue specimens were thawed 
and immediately homogenized in ice-cold 20 mM PBS (pH = 7.4), containing 100 μM 
DTPA and 100 μM BHT, using a Potter-Elvehjem Tissue Homogenizer with PTFE pestle. 
The protein concentration of the tissue homogenate was determined using a Bradford-
based Biorad Protein Assay (Hercules, CA) with BSA as the standard. 
Synthesis and Purification of Isotope Labeled Internal Standards  
Isotope labeled precursors, [13C6] tyrosine and phenylalanine, were purchased 
from Cambridge Isotopes. The purity and isotope composition of each isotope-labeled 
amino acid was confirmed by mass spectrometry analyses to be > 99% pure before use in 
syntheses. Isotope labeled 3-[13C6] bromotyrosine, 3-[13C6] chlorotyrosine, 3,5-[13C6] di-
bromotyrosine, 3,5-[13C6] di-chlorotyrosine, o,o’-[13C12]dityrosine and 3-[13C6] 
nitrotyrosine were synthesized as previously described20, 59, 62. m-[13C6] tyrosine and o-
[13C6] tyrosine were prepared from [13C6] phenylalanine63. Briefly, 3-Bromo [13C6] 
tyrosine and 3,5-[13C6]di-bromotyrosine were prepared by adding fresh made NaOBr to 
an equimolar concentration of L-[13C6] tyrosine solution in 20 mM PBS (pH 7.4) as 
described previously59. The concentration of the NaOBr solution was determined on the 
day of synthesis by UV spectrophotometer (ε331 = 315 M-1 CM-1, 0.1N sodium 
hydroxide). The tyrosine/NaOBr solutions were incubated at 37°C for 2 hours, and 
reactions stopped by the addition of large molar excess of methionine. Prior to HPLC 
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purification, reaction mixtures were treated with trifluoroacetic acid (TFA) to adjust the 
pH to 2.  3-[13C6] chlorotyrosine, 3,5-[13C6] di-bromotyrosine and 3-[13C6] nitrotyrosine 
were synthesized from L-[13C6] tyrosine using an equimolar concentration HOCl, a 2.0 
molar excess of HOCl and equimolar concentration of sodium peroxynitrite, respectively. 
o,o’-[12C12]dityrosine and o,o’-[13C12]dityrosine were prepared by the oxidation reaction 
of L-[12C6] tyrosine and L-[13C6] tyrosine, respectively, with hydrogen peroxide (H2O2), 
catalyzed by horseradish peroxidase. m-[13C6] tyrosine and o-[13C6] tyrosine were 
prepared from [13C6] phenylalanine.  H2O2 and CuSO4 (ratio, 100:1) were used to 
generate the hydroxyl radical used in reactions to oxidize phenylalanine. 
Each synthetic reaction mixture containing isotopically labeled amino acids were 
first partially resolved and desalted using disposable mini solid-phase extraction (SPE) 
columns. Samples were reconstituted with water containing 0.1% TFA and eluted with 
30% methanol and dried under anhydrous nitrogen. The eluted material was individually 
resuspended in chelex 100 (Bio-Rad, Hercules, CA) resin treated water and DTPA (final 
concentration 100 μM) was added before loading material onto a reversed-phase 
Ultrasphere ODS column (Beckman Instruments, Fullerton, CA, 10 mm x 250 mm, 5 μm 
particle) for further purification. L-[13C6] ring labeled tyrosine and its oxidized products 
were separated using reverse-phase HPLC using a diode array detector with dual 
wavelength detection capability at 254 and 280 nm. Amino acids were eluted with a 
linear gradient generated with solvent B (methanol). Universally labeled [13C9, 15N1] 
phenylalanine as commercially supplied was noted to typically require purification by 
reverse-phase HPLC prior to use to eliminate trace amounts of contaminating universally 
labeled ortho- and meta- tyrosine species. 
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Before isolating isotopically labeled amino acids, the corresponding non-labeled 
amino acids were used to optimize HPLC chromatographic condition, identify elution 
times and develop calibration curve. After thorough rinsing of the HPLC system to avoid 
isotope contamination from carry-over, individual internal standards were subsequently 
purified by HPLC. The identity and purity of isotopically labeled standards were 
individually confirmed by HPLC with on-line high-resolution mass spectrometry. The 
isotope labeled internal standards were dried in a speed vacuum and stored at –20 °C.  
General Procedures  
Samples were maintained under argon to prevent artificial oxidation during 
sample handling. In the event that samples could not be analyzed immediately, they were 
purged with argon in gas-tight Cryovials (Corning Inc., Acton, MA), snap-frozen in 
liquid nitrogen and stored at –80 °C. All buffers were treated with chelex-100 resin to 
remove traces of residual transition metal ions. All glassware was treated with DTPA, 
rinsed with chelex-100 resin treated water, and baked at 500 oC overnight prior to use. 
The HPLC columns, filters, and solid phase extraction columns were also rinsed with 
DTPA at neutral pH, and then cleaned with chelex-100 resin treated water. These 
procedures were found necessary to preclude intrapreparative formation of o-tyrosine and 
m-tyrosine during sample hydrolysis and analysis. 
Desalting and Delipidation  
Typically, samples are processed in batches of 50 or less. Samples (20 μL plasma 
or 600 μg tissue homogenate) were diluted to 500 μL with H2O and spiked with DTPA to 
achieve a final concentration of 100 μM. Ice-cold methanol (1.5 mL) and water saturated 
ether (4 mL) were then added sequentially. The mixture was vortexed and maintained in 
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a slush ice-bath for 20 minutes and then centrifuged at 2500 g for 20 min. The 
supernatant was discarded and the protein pellet was briefly dried under a nitrogen stream 
in an N-EVAP nitrogen evaporator (Organomation Associates Inc., Berlin, MA). 
Desalting and delipidation was repeated one more time in the absence of DTPA 
supplementation. The resulting protein pellet was dried under nitrogen prior to protein 
hydrolysis. 
Protein Hydrolysis 
Known amounts of universally labeled [13C9,15N1] tyrosine (4 nmol) and 
[13C9,15N1] phenylalanine (4 nmol) and 13C6-ring labeled internal standards (20 pmol each) 
were added to the protein pellet, followed by the addition of 0.5 mL 4 M methanesulfonic 
acid containing 1% phenol and 0.3% benzoic acid. Hydrolysis of the desalted protein 
pellet was carried out under argon at 110 °C overnight (~18 hours).    
Solid Phase Extraction 
Protein hydrolysates were subjected to solid-phase extraction (SPE) to remove 
acid and concentrate the analytes prior to LC/ESI/MS/MS analysis. Hydrolysates (0.5 mL) 
were adjusted to 2 mL with Chelex-treated water and passed over a C18 solid phase 
extraction column (Supelco Inc., Bellefonte, PA). The column was preconditioned with 6 
mL methanol, rinsed with 6 mL 50 mM PB buffer containing 100 μM DTPA (pH 7.0), 
followed by 6 mL Chelex-treated water and equilibrated with 0.1% TFA water. 
Following sequential washes with 2 mL of 0.1% TFA water, the oxidized amino acids 
and their precursors were eluted with 2 mL 30% methanol solution supplemented with 
0.1% TFA.  Samples were dried under vacuum (Speed Vac) and resuspended with 120 
μL Chelex resin-treated water prior to analysis by mass spectrometry.  
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Instrumentation  
LC/ESI/MS/MS analysis of oxidized amino acids and their precursors was 
performed using a triple quadruple mass spectrometer (ABI/Sciex 365, Applied 
Biosystems, Foster city, CA) equipped with Ionics (Concord, Ontario, Canada) EP 10+, 
EP XP, and HSID upgrades with electrospray ionization (ESI) needle connected to an 
Aria LX4 series multiplexed HPLC system with Flux pumps (Cohesive Technologies, 
Franklin, MA).  The amino acid standards were separated over four matched Prodigy C18 
columns (Phenomenex, 150 x 2.0 mm ID, 5 μm particle), each at a flow rate of 0.2 
ml/min (Figure 4.2). Six oxidized tyrosine and phenylalanine species and the 
corresponding precursors were separated within a 16 minute time-frame (2- 18 minutes). 
The mobile phases used were 0.2% formic acid in water (solvent A) and 0.2% formic 
acid in acetonitrile (solvent B). The elution conditions were as follows: the column was 
first equilibrated with 100% A (0% B), held for 2 min at 100% A (0% B) immediately 
after the injection, then a linear gradient was run from 100% A (0% B) to 82% A (18% B) 
over 18 min, the linear gradient was then run from 82% A (18% B) to 20% A (80% B) 
over the next 2 min. The gradient was held at 80% B for 4 min and immediately cycled 
back to 100% A (0% B) for 12 minutes.  
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 Figure 4. 2  Topical Chromatograms of Oxidized Tyrosine Species Obtained with 
Pure Standard Solutions by LC-MS/MS 
Six oxidized tyrosine species and two precursors, the corresponding [13C6] labeled 
internal standard and the universally labeled precursors (i.e. all carbons 13C, all nitrogen 
15N), were spiked into 20 μl HPLC grade water and processed as described in the 
methods. Natural abundance oxidized tyrosine species and the precursors were identified 
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by reverse phase HPLC coupled to tandem mass spectrometry in positive mode.  The 
retention times of Tyr, m-Tyr, diTyr, o-Tyr, Phe, ClTyr, NO2Tyr and BrTyr were 7.5, 9.8, 
11.2, 11.7, 12.7, 14.2, 15.6 and 16.2 minutes respectively.  Each natural abundance 
oxidized tyrosine (arrow), the universally labeled artifact indicator (arrow) were 
identified by the corresponding [13C6] labeled internal standard which posing exact 
retention time and unique parent-daughter transition. As shown in the figure, no 
universally labeled artifacts were detected in hydrolysated standard solution.  
 126
The mass spectrometer was operated in positive ionization mode. The positively 
charged molecules were selected by mass, and focused in the collision chamber 
containing nitrogen gas. Each distinct parent-daughter ion transition was detected by an 
on-line triple quadruple analyzer. The multiple-reaction monitoring (MRM) transitions, 
the mass-charge ratio (m/z) for the molecular cation [MH] + precursor and the 
corresponding product ions, used to detect the amino acid standards and their 
corresponding isotopomers were listed in Table 4.1.  
Instrument parameters were programmed for the ABI/Sciex API 365 with Ionics 
EP 10+, EP XT collision cell upgrade and Hot Source-Induced Desolvation (HSID) 
interface operated in the positive ionization mode. The ion spray needle was maintained 
at 4000 volts. The turbo gas temperature was set at 500 °C. Ultra pure nitrogen was used 
as the nebulizer gas (NEB, 15), curtain gas (CUR, 12) and collisionally activated 
dissociation gas (CAD, 3). The Hot Source-Induced Desolvation (HSID) module was set 
to 300oC. The peak width at the half-height (mass resolution) was set to one mass unit for 
both Q1 and Q3. Other parameters were set as follows: declustering potential (DP), 13 V; 
focusing potential (FP) 20; prefilter (ST) –18; focusing lens 1 (IQ1) –10.6; collision 
energy (CE), 20; entrance potential (EP), 10; collision cell exit potential (CXP), 15. The 
dwell time of each MRM pair was set at 0.1 sec with a 5 msec pause. The electronic 
multiplier detector was set at 2500 volts with the repeller at –250 volts.  
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Table 4. 1  Parent ?Daughter Transition of Analytes 
(Positive Ionization Mode) 
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Statistical Analysis  
Statistical analyses were performed using SPSS version 11.0. Data are presented 
as mean ± SD. Comparisons between groups were performed using two-tailed unpaired 
Student’s t tests with significance determined by p < 0.05.  Spearmen-rank correlation 
coefficients were used to assess associations between oxidized amino acid species.  
4.3 Results 
MS-MS Spectral Analysis of Tyrosine Species 
The Q1 scan ESI/ MS analysis of all natural abundance oxidized tyrosine species 
and their corresponding isotopomers was performed to confirm the purity and isotopic 
pattern of the sample. Two approximately equally abundant ions with mass-charge ratios 
at 260 and 262 were detected in the 3-Bromotyrosine spectrum. The mass-charge ratio 
represents the protonated molecular ion [M+H] +. This isotopic pattern confirms the 
presence of bromine (79Br: 81Br; 49:51). Similarly, the presence of chlorine (35Cl: 37Cl; 
3:1) in 3-Chlorotyrosine was validated by the presence of two ions at m/z 216 and 218 
with the relative intensity of 3 to 1 respectively (data not shown). Multiple reaction 
monitoring (MRM) mode was used to increase specificity. The MRM transitions were 
monitored for each natural abundance analyte, the corresponding isotopic internal 
standard and universally labeled artifact. The loss of ammonia (NH3) from molecular ion 
yields a product ion with m/z at [M +H-17]. The m/z ratios of parent-daughter transitions 
of natural abundance analytes, isotope internal standards and artifact indicators are 
summarized in Table 4.1. Naturally abundant dihalogenated tyrosine species (3, 5-di-
Bromotryosine and 3, 5-di-Chlorotryosine) and their corresponding heavy isotope labeled 
isotopomers were synthesized. The corresponding parent-daughter transition of each 
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dihalogenated tyrosine is summarized in table 4.2. Using current HPLC condition, all of 
the dihalogenated tyrosine species have distinct retention times and do not interfere with 
the detection of mono-halogenated tyrosine and other oxidized tyrosine species.   
Solid-Phase Extraction (SPE) Efficiency  
The SPE extraction efficiencies of oxidized tyrosine species including 
Bromotyrosine, Chlorotyrosine, dityrosine, meta-tyrosine, ortho-tyrosine and nitrotyrosine, 
were evaluated by comparing peak areas of extracted analytes to those of neat standards.  
The SPE recovery of each analyte was calculated from three independence experiments.  
As shown in Table 4.3 A, the extraction efficiency of most of oxidized tyrosine was larger 
than 85% except meta-tyrosine and ortho-tyrosine.  The low recovery of ortho-tyrosine 
and meta-tyrosine was compensated by the loss of corresponding isotope internal standard.  
Thus, the low recovery of meta-tyrosine and ortho-tyrosine had no impact on the linearity 
of the corresponding standard curve.   
Linear Calibration Range and Limits of Detection  
The seven-point standard curve was sequentially diluted from a primary cocktail 
solution that contains natural abundance oxidized tyrosine species and their precursors, 
tyrosine and phenylalaine.  All natural abundance oxidized tyrosine species were 
identified and quantified by the corresponding [13C6] ring labeled isotopomer by 
LC/MS/MS.  The isotope internal standard cocktail which contained known amounts of L-
[13C9, 15N1] labeled tyrosine (4 nmol), phenylalanine (4 nmol) and of [13C6] ring labeled 
oxidized tyrosine species (20 pmol) was added into solutions containing varying amounts 
of natural abundance tyrosine, phenylalanine and oxidized tyrosine species.  The analytes 
and corresponding internal standards were processed and purified as unknown samples.  
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Peak areas of analyte and the corresponding internal standard were integrated by using the 
Analyst Software (Version 1.4) provided by PE Sciex.  The calibration curve was 
determined from peak area ratio vs. concentration ratio using linear regression.  The 
calibration curves for the amino acids are shown in figure 3. The correlation coefficient (r) 
of each oxidized tyrosine species ranged from 0.995 to 0.999.  
The limit of detection (LOD) of each oxidized tyrosine was achieved by injecting a 
known amount of standard solution with a signal to noise ratio larger than 5.  For each 
analyte, the limit of detection (LOD) and limit of quantitation (LOQ) was listed in Table 
4.3 A. 
Reproducibility and Accuracy 
To determine the accuracy and precision of this assay, known amount of natural 
abundance tyrosine, phenylalanine and oxidized tyrosine species at three concentrations 
(low, medium and high) in triplicates were spiked with isotope internal standard cocktail 
and processed with calibration curves.  Back-calculated concentrations of these samples 
were used for determine of accuracy and precision.  The accuracy of the method was 
measured by relative error (RE%=100x Mean/Nominal) and precision was determined by 
the coefficient of variation (CV%=100x standard deviation/ Mean).  The precision values 
of six oxidized tyrosine species were range from 0.0 to 8.48%.  The accuracy values of all 
analytes were range from -13.8 to 6.73% (detail in Table 4.3A).  The ratio of oxidized 
tyrosine and its corresponding precursors were also calculated. The precision values of 
oxidized tyrosine/precursor were range from 0.986% to 10.7% and the accuracy values 
from -4.79 to 10.2% (details in Table 4.3 B).  
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Table 4. 2  Parent ?Daughter Transition of Dihalogenated Tyrosines 
(Positive Ionization Mode) 
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Table 4. 3  Summary of Method Development 
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LOD: Limit of Detection, LOQ Limit of Quantitation The SPE recovery of each analyte 
was calculated from three independence experiments. 
CV (%) = (Standard deviation/mean) x 100 
RE (%) = (Mean/Nominal Concentration) x 100 
 Figure 4. 3  Calibration Curves of Oxidized Tyrosine Species.  
The standard curve of each oxidized tyrosine was generated by incorporation of 
the fixed amount of internal standard and varying levels of the corresponding analyte. 
The resulting standard solutions were processed and analyzed by LC-MS/MS. Each 
standard curve was plotted as peak area ratio versus mol ratio for each analyte. The linear 
regression analysis of graphs revealed r values of 0.999, 0.999, 0.999, 0.999, 0.995, and 
0.999 for m-Tyr, o-Tyr, Cl Tyr, diTyr, Br Tyr and NO2 Tyr respectively.  Data points 
represent the mean of triplicate determinations. 
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Quantification of Protein-bound Oxidized Tyrosine Species in Human Serum 
The normal ranges of each oxidized tyrosine species in human serum was 
determined by analysis of blood collected from 140 healthy volunteers.  The typical 
chromatograms of a serum sample are depicted in figure 4.4. The natural abundance 
tyrosine species were identified and quantified in relation to their corresponding ring-
labeled isotope internal standard. As demonstrated in figure 4.4, there were no detectable 
artifacts, which possess the anticipated m/z transitions for the corresponding universally 
labeled oxidized amino acid. The amount of protein-bound oxidized tyrosine species was 
normalized to its corresponding precursor, tyrosine and phenylalanine respectively. The 
level of each species in healthy subjects is presented in figure 4.5. A strong correlation 
was found between the m-Tyr/Phe and o-Tyr/Phe ratios (R= 0.57, p<0.001). Moderate 
correlations were found between levels of chlorotyrosine with nitrotyrosine (R=0.366, 
p<0.001), bromotyrosine (R= 0.207, p< 0.05), o-tyrosine (R=0.203, p<0.05) and m-
tyrosine (R=0.262, p<0.005) and between levels of bromotyrosine and nitrotyrosine (R= 
0.219, p< 0.01). (Table 4.4) 
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 Figure 4. 4  LC- MS/MS Detection of Oxidized Tyrosine Species in Human Serum 
Human serum (20 μL) was processed as described in the methods. Each natural 
abundance oxidized tyrosine was detected and quantified by the corresponding stable 
isotope labeled internal standard. The typical chromatograph of each analyte and the 
corresponding characteristic MRM transitions was listed above.  The retention time of 
Tyr, m-Tyr, o-Tyr, diTyr, ClTyr, NO2Tyr and BrTyr were 6.1, 9.1, 11.4, 10.5, 13.2, 14.5 
and 15.2 minutes respectively.  
 136
  
Figure 4. 5  Serum Levels of Oxidized Tyrosine in Healthy Volunteers.    
140 serum samples from healthy volunteers were analyzed by LC-MS/MS. The 
result of each oxidized amino acid was normalized to the amount of its corresponding 
precursor.  In the box plots, the lower boundary indicates the 25th percentile, the line 
within the box marks the median, and upper boundary of the box indicates the 75th 
percentile.  Error bars above and below the box indicate 95th and 5th percentile. 
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Table 4. 4  Spearman Correlations Among Oxidized Tyrosine Species 
 
 
 
In 140 healthy volunteer, the serum level of oxidation markers was studied to 
further explore the underlining mechanism of oxidation in vivo.  * p<0.05, ** p<0.01, 
*** p<0.005 and **** p<0.001. 
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Quantification of Oxidized Tyrosine Species in Guinea Pig Lung Tissue 
As thiocyanate (SCN-) is a preferred substrate for EPO, it is possible that 
increased systemic level of SCN- following dietary supplementation may result in 
preferential oxidation of SCN- in comparison with halide species including Br- and Cl-. 
To test this hypothesis, the effect of dietary SCN- supplementation on an aeroallergen 
challenge model of asthma in age- and sex- matched Hartley guinea pigs was determined. 
In animals fed normal chow, lung levels of 3-BrTyr increased following challenge with 
OVA, in comparison with normal saline. This further supports the notion that aerosol 
exposure with OVA is associated with enhanced bromination in lung tissue. However, the 
allergen induced increment of bromination was completely abrogated by dietary 
supplementation with SCN- prior to OVA challenge. This result suggests that dietary 
supplementation with SCN- enriched food may afford relief from oxidative injury of lung 
and airway proteins during the asthmatic response. (Figure 4.6) 
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Figure 4. 6  Comparison of the Levels of Oxidized Tyrosine Species in OVA 
Challenged Model  
Hartley guinea pigs were fed a normal diet (SCN-, n=11) or thiocyanate enriched diet 
(SCN-, n=6).  The animals on normal diet were sensitized with ovalbumin (SCN-, OVA+, 
n=6) or normal saline (SCN-, OVA-, n=5) on days 0 and 14, then challenged later on day 
21 with aerosolized either OVA or normal saline.  OVA challenge were also performed on 
the animal with thiocyanate enriched diet (SCN-, OVA+, n=6). 48 hours after the 
challenge, lungs were harvested and preserved. The oxidized tyrosine species and their 
precursors were quantified by LC/MS/MS. The result of each oxidized amino acid was 
normalized to the amount of the corresponding precursor. Values represent mean ± SD.  
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4.4 Discussion 
As evidence accumulates supporting a pivotal role for oxidized tyrosine species in 
the pathogenesis of a wide range of disease processes, it has become important to develop 
accurate analytical methods to quantify the levels of these products in vivo. The 
generation of oxidized tyrosine species has been implicated in the development of 
atherosclerotic plaque, asthma and breast cancer. In addition, it has been demonstrated 
that protein-bound levels of nitrotyrosine decline in response to statin therapy. These 
molecular fingerprints have the potential to be developed as a marker of disease risk and 
activity. In order to be a useful clinical biomarker it is necessary to develop accurate 
analytical methods that can rapidly and reproducibly quantify levels in a range of 
biological matrices. The use of the bench top triple quadrupole LC/MS/MS method 
described in this report fulfills these criteria.   
The method can be subject to modification depending on the clinical scenario. 
Biological matrices containing high levels of endogenous nitrite/nitrate, such as salivary 
fluid and endobronchial aspirates, often require additional desalting steps. In addition, 
different methods for protein hydrolysis can be used, depending on the oxidized species of 
interest. As the described method aims to measure levels of multiple oxidized species 
simultaneously, methanesulfonic acid is typically used. In contrast, when it is unnecessary 
to measure chlorotyrosine levels, acid hydrolysis is often performed using hydrochloric 
acid. Similarly, the total monitored precursor-product transitions can be adjusted to fulfill 
the requirement of sensitivity and specificity. When using different biological matrices, 
protein concentration and extraction procedure should be re-evaluated to eliminate ex vivo 
artifacts generation prior to proceeding with sample assays.  
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The CVs of QC samples (oxidized tyrosine/precursor, three concentrations in 
triplicates) were ranged from 0.986 to 10.7%.  To determine the coefficient of variations 
of real samples, five replicates of two human serum samples were also processed and the 
CV of protein-bound of bromotyrosine, chlorotyrosine, dityrosine, meta-tyrosine, ortho-
tyrosine and nitrotyrosine were range from 11 to 22%, 25 to 30%, 22 to 33%, 13 to 18%, 
14 to 18%, and 29 to 30%.  The high variations of protein-bound of oxidized tyrosine 
species may reflect the complex of oxidized tyrosine residue in sample and the variation 
of protein recovery during desalting and delipidation step. 
This analytical method can be particularly useful because it can be applied to a 
large number of samples simultaneously. Furthermore, it demonstrates a high sensitivity 
and specificity for the detection and quantification of a number of oxidized species at the 
same time. The low limit of detection of standard samples is consistent with previous 
reports of assays using triple quadrupole systems. Incorporation of heavy isotope labeled 
internal standards that assist in the detection of artifactual generation of oxidized products 
ex vivo during sample preparation is a key component of this assay. Using these standards, 
we have found that the degree of artifactual oxidation is minimal. In the rare event that the 
level of artifactual species exceeded 5% of the total level detected, we repeated the sample 
preparative step with a more exhaustive desalting step. In certain circumstances it is 
necessary to modify the sample preparation to eliminate intra-preparative artifacts 
generation. In patients receiving nitrate therapy in the setting of acute coronary syndromes, 
an extra desalting step is often required to remove the excess nitrate when assaying 
nitrotyrosine levels.  
 142
The ability to determine levels of multiple oxidized markers in biological samples 
expands our understanding of the role of particular oxidative pathways in the pathogenesis 
of a range of disease processes. The correlations between individual oxidized species, 
demonstrated in the serum of healthy volunteers, provides insight into the pathways that 
generate these species in vivo. The strong correlation between levels of m-tyrosine and o-
tyrosine highlights the role of phenylalanine hydroxylation. Similarly, correlations 
between the level of 3-ChloroTyrosine with both 3-NitroTyrosine and 3-BromoTyrosine, 
and between levels of 3-BromoTyrosine and 3-NitroTyrosine, are consistent with in vivo 
activity of myeloperoxidase and eosinophil peroxidase respectively. These relationships 
provide chemical evidence that pathways induced by leukocyte activation contribute to the 
generation of oxidative stress in vivo. The current study adds further support for the notion 
that bromination, catalyzed by the leukocyte derived enzyme eosinophil peroxidase, is 
enhanced in an animal model of aeroallergen challenged asthma.  In addition, elevated 
peripheral SCN- from dietary supplement partially inhibits EPO catalyzed protein 
bromination in vivo.  Increase systemic level of SCN- may become a potential strategy for 
therapeutic intervention of EPO induced oxidative modification.  
In summary, the current report describes the development of an analytical method 
using a bench top triple quadrupole LC/MS/MS system that reliably detects and 
quantifies oxidized tyrosine species and their precursors in a wide range of biological 
matrices. This method avoids the need for chemical derivatization of samples and 
minimizes the possibility that artifactual generation of oxidation products may interfere 
with the detection of native levels. The evolution of bench top mass spectrometric 
systems allows for the ability to analyze multiple samples simultaneously. As a result, the 
 143
detection of levels of oxidized products in biological samples has provided further 
insights into the specific oxidative pathways that promote the pathogenesis of a wide 
variety of disease processes. 
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 CHAPTER V  
NASAL MUCOSA IS A SANCTUARY SITE FOR ENHANCE 
OXIDATIVE STRESS AS REVEALED BY MOLECULAR 
FOOTPRINTS OF MULTIPLE OXIDATIVE PATHWAYS 
 
5.1  Introduction 
The mucosal lining of the nose and paranasal sinuse serves as an important barrier 
between the host and the external environment.  This barrier function occurs in two 
principal ways.  Firstly, the mucosa provides a physical covering that blocks the entry by 
potentially pathogenic micro-organisms and non-living substances.  Secondly, the 
immune system performs its surveillance function against non-self antigens within the 
mucosa and along its surface.  The immune system targets specific antigens through the 
processes of adaptive immunity, which is mediated by both T- and B-cells.  Innate 
immunity provides nonspecific protection against nonself antigens.  Mechanisms for 
innate immunity include phagocytosis (by neutrophils, monocytes and macrophages),  
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 the complement cascade and peroxidases (secreted by neutrophils, monocytes, 
eosinophils, etc.).  Because innate immunity is intrinsically nonspecific, its action may 
inadvertently damage host tissues.  Derangements of immune system function in 
sinonasal mucosa lead to a wide variety of chronic inflammatory conditions, including 
allergic rhinitis (AR) and rhinosinusitis (RS, previously termed sinusitis).       
Approximately 31 million Americans report suffering from RS 1.  The hallmark of 
this condition is a chronic inflammatory infiltration 2.  The etiology of RS is unknown 
bacteria, fungus and immunological dysfunction.  Outcome studies have confirmed that 
RS has a large adverse impact on patient quality of life measures including reductions of 
patient sense of physical, functional and emotional well-being 3 4.  
Once activated, eosinophils and neutrophils are recruited to the sites of 
inflammation and release unique leukocytes peroxidases and cytotoxic granule proteins, 
including major basic protein (MBP) 5.  The leukocytes peroxidases, eosinophil 
peroxidase (EPO) and myeloperoxidase (MPO), are some of the most abundant proteins 
in these cells 6 7. In the past several years, studies suggest that EPO and MPO utilize 
H2O2 with halides or pseudohalides as co-substrates to generate reactive hypohalous acid 
(HOX): H2O2 + X- + H+ ? HOX + H2O (X= Br-8, Cl- 9, I- 10 and SCN- 11 respectively) to 
fight invading pathogens 12. Although peroxynitrite (ONOO-), the reactive species formed 
by nitric oxide radical (NO˙) and superoxide (O2˙-)13, is believed the major reactive 
nitrogen species (RNS), recent studies support EPO and MPO may also participate to 
generation of RNS14-16. Using free or protein-bound tyrosyl residues as substrate, 
EPO/MPO also participates the formation of tyrosyl radical 17.  Further, redox-active 
metal ions interact with H2O2 to generate hydroxyl radical (HO˙)18(Fig. 5.1.).   
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Figure 5. 1  Reactive Intermediates Generated by Enzymatic Ppathways and Free 
Metal Ions React with Tyrosine and Phenylalanine  
EPO and MPO utilize hydrogen peroxide and various substrates, including 
bromide, chloride, tyrosine and nitrite (NO2-) to generate an array of reactive 
intermediates: hypobromous acid and hypobromite ion (HOBr/OBr-), hypochlorous acid 
and hypochlorite ion (HOCl/OCl-), tyrosyl radical and nitrogen dioxide (NO2˙). Another 
reactive nitrogen species, peroxynitrite (ONOO-), is generated by the interaction of nitric 
oxide radical with superoxide.  Redox-active metal ion (free or protein-bound) reacts 
with hydrogen peroxide to generate hydroxyl radical (˙OH). These reactive intermediates 
react with tyrosine or phenylalanine to generate distinct molecular fingerprints of 3-
BrTyr, 3- 3-ClTyr, di Tyr, 3-NO2Ty, m-Tyr and o-Tyr, respectively. 
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These reactive oxidants provide host defense mechanisms against pathogenic 
organisms through oxidative modifcation.  Obviously, the reactions of RBS, RCS, RNS, 
tyrosyl radical, hydroxyl radical and peroxynitrite are all non-specific, and inevitably host 
tissues can be modified through these oxidations.  Host tissue injury may be assessed 
through quantifying the amounts of stable end-products, which serve as a molecular 
footprint of the oxidative modification.  Previous studies have demonstrated that RBS, 
RCS, RNS and tyrosyl radicals oxidize protein-bound tyrosine residues to produce 3-
bromotyrosine (3-BrTyr)19, 20, 3-chlorotyrosine (3-ClTyr) 21, 22, 3-nitrotyrosine (3-NO2Tyr) 
15, 23 and o, o’-di-tyrosine (di Tyr) 24, respectively. Similarly, hydroxyl radicals convert 
protein-bound phenylalanine residues to meta-tyrosine (m-Tyr) and ortho-tyrosine (o-
Tyr). 25, 26 
The current study seeks to demonstrate patterns of oxidative metabolism in 
sinonasal mucosa under normal conditions and in the presence of chronic inflammation.  
This approach highlights the presence of oxidants produced by both EPO and MPO under 
normal, healthy conditions.  In addition, this method may serve as a powerful tool for the 
study of mechanisms of RS pathogenesis. 
5.2 Experimental Procedures 
Subjects 
RS patients (n=42) were recruited from the clinical practices of the Section of 
Nasal and Sinus Disorders in Cleveland Clinic Foundation Head & Neck Institute.  A 
symptom-based history of chronic RS, as defined by the criteria established by the Sinus 
and Allergy Health Partnership27, was present in all RS patients.  All RS patients reported 
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 symptoms of rhinorrhea and nasal obstruction, and the clinical diagnosis was confirmed 
through nasal endoscopy and CT scan.  Atopy was assessed through a RAST inhalent 
panel that measured specific IgE for a variety regionally relevant allergens (specific IgE 
to Timothy grass, June grass, Bermuda grass, short ragweed, English plantain, Lamb’s 
quarters, box elder tree, oak tree, Elm tree, cat dander, dog dander, Penicillium notatum, 
Cladosporium herbarum, Aspergillus fumigatus, Alternaria tenuis, house dust and 
Dermatophagoides farinae analyzed by ImmunoCap, Pharmacia & Upjohn, Kalamazoo, 
MI). RS patients with a positive RAST panel (defined as detectable Class I or greater 
reaction for one or more antigens) were grouped into the allergic rhinosinusitis (ARS) 
group, while the remaining patients with a negative RAST panel were grouped into the 
nonallergic rhinosinusitis (NARS) group. 
A total of 16 volunteers were recruited by local advertisements following 
informed consent.  Only ten subjects who were at least 25 years old with normal Ig E and 
RAST panel were eligible to enroll into study.   
The Cleveland Clinic Foundation Institutional Review Board approved the 
protocol. 
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 Table 5. 1  Population Characteriistics 
 
 
Controls 
(n=10) 
Rhinosinusitis (RS) 
(n=42) 
Age (Mean ± SD) 28.1 ± 7.7 51.4 ± 11.3** 
Male gender (%) 60 60 
IgE (Unit per ml) 21.7 ± 20.2 263.1 ± 522.5* 
Eosinophil differential (%) 2.8 ± 1.5 5.1 ± 3.4* 
Abnormal RAST panel (%) 0 40** 
Asthma (%) 0 50** 
Steroid (%) 0 70** 
Comparison RS vs. control:  * = p< 0.01, ** = p< 0.01;  
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 Sample Collection and Storage 
Sinonasal mucosa was obtained from RS patients under endoscopic visualization, 
and middle turbinate biopsies were performed in control subjects under endoscopic 
visualization.  Approximate tissue size was 3 mm x 3 mm x 3 mm.  Tissue samples were 
immediately placed in the ice-cold antioxidant phosphate buffer (100 µM DTPA, 100 µM 
BHT, PB, 20 mM, pH 7.4) and overlaid with argon and saved in approximately –80 °C 
until analysis. 
At the time of biopsy, sera samples were collected from all subjects.  Sera 
samples were then spiked with anti-oxidant cocktail (100 µM DTPA, 100 µM BHT), 
covered by argon layer and stored frozen at approximately –80 °C freezer. 
Preparation of Tissue 
All samples were processed on the date of analysis. Tissue specimens were 
thawed and immediately homogenized in ice-cold PBS buffer (100 μM DTPA, 100 μM 
BHT, PB= 20mM, pH = 7.4) using a Potter-Elvehjem Tissue Homogenizer with a PTFE 
pestle.  A Bradford-based Biorad (Hercules, CA) Protein Assay with human serum 
albumIn (HSA) as the standard was used for determination of protein concentration. 
Materials 
All solvents were purchased from Fisher Chemical Co. (Pittsburgh, PA,) and were 
the highest or HPLC grade.  All other reagents were purchased from Sigma (St. Louis, 
MO,) unless otherwise indicated.  All gasses were of highest quality available and were 
from Praxair (Cleveland, OH).  Isotopically labeled amino acids were from Cambridge 
Isotopes (Andover, MA).  
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 Preparation and Purification of Isotope-labeled Internal Standard 
Isotopically labeled 3-[13C6] bromotyrosine, 3- [13C6] chlorotyrosine, and 3-[13C6] 
nitrotyrosine and o, o’-di Tyrosine were synthesized as previously described 17, 19, 28, 29.  
m-[13C6] tyrosine and o-[13C6] tyrosine were synthesized using [13C6] phenylalanine, 
copper and H2O2 30. Each isotopically labeled compound solution was purified by 
reversed-phase HPLC and collected at the exactly same retention time of the 
corresponding natural abundance oxidized tyrosine.  The identity and purifity of isotop 
internal standard was confirmed by LC/MS. 
General Procedures 
To prevent the artificial oxidation during sample handling, samples were always 
kept under argon.  All buffers were treated with chelex-100 resin (Bio-Rad, Hercules, CA) 
to remove residual amount of transition metal ions. The glassware was treated with 
DTPA, rinsed with chelex-100 resin treated water, and baked at 500o C overnight prior to 
use.  
Desalting and Delipidation 
The quantity of 20 µl serum or 600 µg tissue homogenate was spiked with DTPA 
(final concentration100 μM) and adjusted to 500 μl with Chelex-resin treated water.   
Ice-cold methanol (1.5 ml) was added and followed by diethyl ether (4 ml, water 
saturated).  The resulting solution was gently vortexed and incubated in an ice-bath for 20 
minutes. The suspension was spun down at ~ 4000 rpm for 20 minutes. The supernatant 
was discarded and the protein pellet was dried under nitrogen. Desalting and delipidation 
was repeated again using the procedure above without DTPA supplementation. 
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 Protein Hydrolysis 
The protein or tissue residue was dried under nitrogen piror to addition of 
isotopically labeled internal standard cocktail.  The sample was then hydrolyzed at  
110 °C for 20 hours in 0.5 ml methane sulfonic acid (MSA, 4 N) with 1% phenol and 
0.3% benzoic acid supplement.  
Solid Phase Extraction 
Protein hydrolysates were diluted to 2 ml with Chelex-treated water and passed 
over a C18 SPE column (500 mg, Supelco Inc., Bellefonte, PA). The column was 
pretreated with 6ml methanol, rinsed with 6ml PB buffer (50 mM, pH 7.0, 100 μM 
DTPA), followed by 6ml Chelex-treated water and equilibrated with 6 ml 0.1% TFA 
water. After 2 x 2 ml of 0.1% TFA water wash, the amino acids were eluted with 2 ml 
30% methanol in water containing 0.1% TFA. The samples were dried under speed vac 
and re-dissolved in 120 μl chelex-treated water before analysis by mass spectrometer. 
Instrumentation 
Amino acids were quantified by stable isotope dilution LC-MS/MS. Each 60 μl 
sample was analyzed on a Quattro Ultima mass spectrometer (Waters, Altrincham, U.K.) 
interfaced with a Waters 2690 Separation Module HPLC system (Waters, Milford, MA, 
USA).  The source temperature was set at 250 °C.  The cone and capillary voltages were 
optimized at 30 V and 5 KV respectively.  The collision energy was set to 15 eV with a 
dwell time of 100 ms for each analyte.  
The positively charged molecules were selected by mass-charge ratios and 
focused in the collision chamber containing argon gas. The multiple-reaction monitoring 
(MRM) transitions were used to detect oxidized tyrosine species and their precursors, 
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 tyrosine and phenylalaine, respecitvely. Each distinct parent-daughter transition was 
detected by triple quadruple analyzer.  The molecular ions of 3-BrTyr (M+) in positive 
mode are m/z 260 [79 Br], 262 [81Br].  The product ion of 3-BrTyr include m/z 243 ([79Br] 
M+ -NH3), 245 ([81Br] M+ -NH3), 214 ([79Br] M+ -CO2H2), and 216 ([81Br] M+ -CO2H2). 
The parent-daughter transition 260 ? 214 was used to quantify 3- Br Tyr.  Similarly, the 
transitions of 218 ? 172, 361 ? 315, 227 ? 181 and 166 ? 120 were used to quantify 
3-ClTyr, di Tyr, 3-NO2 Tyr and phenylalanine respectively. Tyr, m-Tyr and o-Tyr use 
same parent-daughter transition 182 ? 136, with different retention times. 
A Prodigy ODS 18 column (150 x 2 mm, 5 μm resin, Phenomenex, Torrance, CA, 
USA) was used to separate amino acids at a flow rate of 0.2 ml/min. The column was 
equilibrated with solvent A (0.2% formic acid in water) first. Then the analytes were 
separated by a stepped linear gradient with solvent B (0.2% formic acid in acetonitrile) as 
follow: 0% solvent B was held for 2 min, followed by a linear change from 0% B to 18% 
B over 18 min, then hold at 80% B in next 2 min. The gradient was then kept at 80% B 
for 4 min before return to 0% solvent B. 
Statistical Analysis 
Data are presented as mean ± SD.  The statistic studies were performed using 
SPSS version 11.0 (SPSS. Inc. Chicago, IL).  The significance level was set at 95%. 
5.3 Results 
Oxidized Tyrosine Species in Nasal Mucosa in Normal Subjects  
Amino acids isolated from acid hydrolysates of nasal mucosa were analyzed by 
LC-MS/MS as described in experimental procedures. The identity of each authentic 
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 oxidized tyrosine was confirmed by the corresponding isotopically labeled internal 
standard possessing identical retention time (Figure. 5.2). 
Elevated o-Tyr, 3-BrTyr, and 3-ClTyr in Healthy Nasal Mucosa  
To explore the mechanisms of leukocyte-catalyzed oxidative damage in healthy 
sinonasal mucosa, the peripheral serum level of each oxidized tyrosine species and the 
corresponding sinonasal tissue level were compared.  In normal subjects, protein-bound 
3-BrTyr level was significantly elevated in sinonasal tissue compared with that in serum 
(556.9 µmol/mol vs. 40.0 µmol/mol, p<0.01).  Levels of protein-bound tissue o-Tyr and 
3-ClTyr in tissue were also observed (o-Tyr, 394.0 µmol/mol vs. 190.1 µmol/mol, p<0.05; 
3-ClTyr/Tyr, 10.9 µmol/mol vs 5.3 µmol/mol, p<0.05).  No other significant differences 
between systemic and local levels of m-Tyr and diTyr were noted in healthy volunteers, 
although there were trends toward higher levels in nasal mucosa (Figure. 5.3A).  
Elevated m-Tyr, o-Tyr, di Tyr, 3-BrTyr, and 3-NO2Tyr in Nasal Mucosa from RS 
Patients 
In RS subjects, levels of m-Tyr, o-Tyr, di Tyr, 3-BrTyr and 3-NO2Tyr  were all 
elevated in sinonasal tissue compared with serum (m-Tyr, 131.4 µmol/mol vs. 88.4 
µmol/mol, p< 0.01; o-Tyr, 458.0 µmol/mol vs. 213.5 µmol/mol, p< 0.001; diTyr, 5449.9 
µmol/mol vs. 536.0 µmol/mol, p< 0.001; 3-BrTyr, 897.5 µmol/mol vs. 35.1 µmol/mol, 
p< 0.001; 3-NO2Tyr, 43.9 µmol/mol vs. 17.6 µmol/mol, , p< 0.05) (Figure 5.3 B).  
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Figure 5. 2  Chromatograph of Oxidized Tyrosine Species in Nasal Tissue 
Specimen from a Rhinosinusitis Patient  
Nasal tissue specimen was obtained from a RS patient and prepared as described 
in Experimental Procedures. m-Tyr, o-Tyr (MRM: 182 ? 136), diTyr (361 ? 315), 
ClTyr (218 ? 172) and NO2Tyr (227? 181) were quantified by the corresponding 
isotope internal standard, [13C6] m-Tyr, o-Tyr (MRM: 188 ? 142), [13C12] diTyr (373 ? 
327), [13C6] ClTyr (224 ? 178) and [13C6] NO2Tyr (233? 187) and [13C6] BrTyr (266? 
220). 
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Figure 5. 3  Sinonasal Tissue and Peripheral Serum Levels of m-Tyr, o-Tyr, 3-
BrTyr, 3-ClTyr, 3NO2Tyr and di Tyr   
Panel A, comparisons of tissue and serum levels oxidized tyrosine species from 
control subjects (n=10).  The levels of o-Tyr, 3-BrTyr and3-ClTyr in sinonasal tissue 
were significantly elevated. Panel B, comparisions of tissue and serum levels oxidized 
tyrosine species from RS patients (n= 42).  Sinonasal levels of m-Tyr, o-Tyr, 3-BrTyr, 3-
NO2Tyr and di Tyr were significantly elvelated. Data represent the mean ±SD.   
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 Sgnificantly Elevated Bromination and Tyrosylation in RS Patients Compare to 
Those in Healthy Controls 
To understand the mechanism of oxidative modification in nasal mucosa, the 
tissue/serum ratio (T/S ratio) of each oxidized tyrosine species was calculated to 
normalize individual differences.  T/S ratios greater than one were noted for all analytes 
indicating an elevated oxidative stress in sinonasal tissue.  TheT/S ratios in RS patients 
were significant greater than corresponding T/S ratios in control subjects (T/S ratio (mean, 
μmol/mol/ μmol/mol), 3-BrTyr, RS, 27.0, control, 15.5, p<0.005; diTyr, RS, 18.4, control, 
4.9, p< 0.05) (Figure. 5.4.). However, the T/S ratio for m-Tyr, o-Tyr, 3-ClTyr and 3-
NO2Tyr was similar in RS patients and controls (T/S ratio (mean, μmol/mol/ μmol/mol), 
m-Tyr, control, 1.8, RS, 1.7, p=0.90; o-Tyr, control, 2.2, RS, 2.3, p= 0.79; 3-ClTyr, 
control, 3.4, RS, 3.0, p=0.72; NO2Tyr, Control, 2.9, RS, 2.8, p= 0.94.).   
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Figure 5. 4  Bromination and Tyrosylation Were Significantly Increased in RS 
Patients Compared with Control Subjects    
The tissue/serum ratio of each oxidized tyrosine was calculated to normalize 
individual differences. Elevated bromination and tyrosylation were significantly 
increased in RS patients compared to those in controls (3-BrTyr T/S ratio, RS, 27.0± 11.6, 
control, 15.5± 8.1, p< 0.005; di Tyr T/S ratio, RS, 18.4± 25.8, control, 4.9 ± 7.8, p< 0.05).
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5.4 Discussion 
Human eosinophils produce reactive brominating species which can serve as 
oxidants to participate host defense and may also cause host tissue damage 8, 20.  Previous 
in vitro data have demonstrated that peroxidases can utilize physiological levels of 
halides or pseudohalides as co-substrates to generate reactive hypohalous acid even in the 
presence of multiple competing co-substrates 17.  Eosinophil activation and induced 
oxidative modification were observed in numerous biological matrixes.  Recent studies 
found that significantly elevated protein-bound 3-BrY was recovered in sputum, 
bronchoalveolar lavage fluid (BAL) in asthmatic patients compared to the healthy 
controls 20, 31.  Elevated serum eosinophil is the hallmark of a chronic inflammatory in 
rhinosinusitis patients 2, 5.  In the current study, the tissue levels of 3-BrTyr were 
significantly elevated in RS patients compared to that in control group (3-BrTyr, RS 
(n=42) vs. Control (n=10), 871.1 µmol/mol vs. 556.9 µmol/mol, p< 0.05).  However, half 
of RS patients (n= 21) had asthmatic symptoms.  Therefore, the potential impact of 
asthma on protein oxidative damage in nasal tissue was investigated.  Significantly 
elevated 3-BrTyr was detected in nasal mucosa in RS patients with or without asthmatic 
symptom compared with control groups (3-BrTyr (µmol/mol), RS with asthma vs. 
control, 861 vs.556.9, p< 0.05; RS without asthma, 881 vs.Control, 556.9, p< 0.05).  But 
there was no significant different in 3-BrTyr in nasal mucosa between RS patients with or 
without asthma (3-BrTyr (µmol/mol), RS with asthma, 861 vs. RS without asthma, 881, 
p= 0.856).  The present study strongly suggests that asthmatic inflammation has no 
significant impact on the augment of bromination in nasal mucosa in RS patients.  Thus 
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 the elevation of 3-BrTyr levels supports activation of eosinophils in RS pathophysiology.  
In this way, EPO-catalyzed oxidation may play central roles in fighting pathogens and 
inadvertently in inducing non-specific host tissue oxidation.  
This report describes both nasal mucosal tissue and serum levels of a panel of 
oxidized tyrosine species in healthy control subjects as well as RS patients.  Even in 
healthy controls, tissue levels of o-Tyr, 3-ClTyr and 3-BrTyr were significantly higher 
than the corresponding serum levels.  Thus, under physiological conditions, nasal mucosa 
serves as a sanctuary site for oxidative stress, as measured by dramatic elevations of 
oxidized tyrosine residues in nasal mucosa from healthy subjects.  The presence of 
evidence of oxidative stress in health nasal mucosa is not surprising in light of the barrier 
function provided by the nasal mucosa.  The nasal cavity serves as a ‘trap’ for inhaled 
micro-organisms and particulate matter.  Removal of this foreign material occurs through 
the active transport of mucus in the process of mucociliary clearance.  Surveillance 
provided by the immune system also occurs in the interface provided by the mucosa.  
Since peroxidases released by inflammatory cells play an important role in the 
inactivation of invasive micro-organisms and particulate matter, evidence of their activity 
in healthy mucosa, where normal clearance of these non-self antigens is an active (and 
successful) process that should be expected. 
In RS patients, m-Tyr, o-Tyr, 3-BrTyr, diTyr and 3-NO2Tyr were all elevated in 
nasal tissue compared with that in serum, suggesting a more generalized elevation of 
oxidative stress in the tissues.  This more generalized elevation of the oxidative stress in 
sinonasal mucosa in RS patients probably reflects the underlying RS disease process of 
inflammatory infiltration of the sinonasal mucosa.   
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 To further investigate the involvement of each distinct oxidative pathway in nasal 
inflammation, RS patients were divided into two subgroups, allergic rhinosinusitis (ARS, 
n=17) and nonallergic rhinosinusitis (NARS, n=25).  Sinonasal tissue 3-BrTyr level was 
significantly increased in NARS patients compared with controls (3-BrTyr (µmol/mol), 
NARS, 927.7 vs. Control, 556.9, p <0.05).  Sinonasal tissue levels of 3-BrTyr were 
elevated but not reach statistic significant in the ARS and control groups (3-BrTyr 
(µmol/mol), ARS, 787.8 vs. Control, 556.9, p =0.11), and no significant differences in 
sinonasal tissue 3-BrTyr levels in NARS and ARS were noted (3-BrTyr (µmol/mol), 
NARS, 927.7 vs. Control 787.8, p =0.20) (Figure 5.5 A.).  In addition, sinonasal tissue  
di-Tyr was significantly increased in ARS patients compared with control subjects  
(di Tyr (µmol/mol), ARS, 5753.0 vs. Control, 2028.3, p <0.05).  Sinonasal tissue levels 
of di-Tyr were elevated but not statistic significant in the NARS and control groups (di 
Tyr (µmol/mol), NARS, 4970.9 µmol/mol vs. Control, 2028.3, p =0.08), and no 
significant differences in sinonasal tissue di Tyr levels in ARS and NARS were noted (di 
Tyr (µmol/mol), ARS, 5753.0 vs. NARS, 4970.9, p =0.72). (Figure 5.5B.).  Since the 
mechanisms for nonallergic and allergic inflammation are often considered distinct, the 
failure to identify many differences between allergic and nonallergic RS is surprising.  
Perhaps, enhanced oxidative stress is a common feature of RS associated with allergic 
and nonallergic inflammatory mechanisms. 
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Figure 5. 5  Distinct Oxidation Pathway Was Elevated in non-allergic 
Rhinosinusitis (NARS) and Allergic Rhinosinusitis (ARS) Compared with Control  
A, tissue 3-BrTyr levels in control (n=10), ARS (n=17) and NARS (n=25) were 
compared. Significantly elevated sinonasal tissue 3-BrTyr levels were only observed in 
NARS compared to control (NARS, 927.7 µmol/mol vs. Control, 556.9 µmol/mol,  
p <0.05).  In panel B, tissue levels of di-Tyr in control, ARS and NARS subjects were 
compared.  Significantly elevated tissue level diTyr were observed in ARS patients 
compared to controls (ARS, 5753.0 µmol/mol vs. Control, 2028.3 µmol/mol, p <0.05). 
No other significant differences were observed between ARS vs. Control and NARS vs. 
ARS. 
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Our previous study indicated that systemic level of protein-bound nitrotyrosine 
declined in response to the treatment of with statins 32.  The primary design of current 
study was not focused on the impact of anti-inflammation action of steroid on the 
observed levels of oxidative markers.  But due to general steroid usages in RS patients is 
about 70%, it may have certain impact on reducing eosinophils, neutrophils and may 
modulate the observed levels of bromination at serum and tissue level.  Therefore the 
serum level of 3-BrTyr was compared between RS patients with or without steroid usage.  
No significant difference in bromination was observed between RS patients with or 
without steroid usage at serum level (3-BrTyr (µmol/mol), RS with steroid vs. RS 
without steroid, 35.1 vs. 34.9, p= 0.95).  However, in RS patients with tissue level 3-
BrTyr ≤ 658.6 µmol/mol (T1), 64% of them had steroid treatment.  The steroid usage was 
increased to 86% when RS patients with tissue levels of 3-BrTyr were greater than 
1027.9 µmol/mol (T3).  The trend did not reach statistic significant due to limit study 
number, various brands steroid usages.  In addition, without the oxidative profile prior to 
treatment, the therapeutic impact of steroid at inflammation site is still unsolved.  Future 
study the correlation of oxidative modification in nasal mucosa in response to steroid, 
especially nasal steroid treatment is necessary.   
5.5 Conclusion 
The elevations of oxidized tyrosine species in healthy nasal mucosa (compared 
with corresponding serum levels) suggests that oxidative stress occurs in nasal tissue 
under normal physiologic conditions. Furthermore, detection of end products of oxidative 
metabolism in normal tissue supports the concept that nasal mucosa is a sanctuary site for 
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 host defenses against potentially pathogenic micro-organisms and other foreign antigens.  
RS patients show an even higher level of oxidative stress in nasal tissue.  Thus, activation 
of oxidative pathways may contribute to RS pathogenesis. 
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